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In this introduction, I briefly review the natural history and pathogenesis of Tuberculosis (TB), with 
a focus on paediatric TB. This is followed by a summary of the global disease patterns and trends. 
Accordingly, I discuss the need for a new TB vaccine and the factors affecting low efficacy of the 
current extant vaccine. Given that there are potentially different vaccination strategies and targets, I 
review the selection of the target population, diagnostic considerations and practical elements for TB 
vaccine sites. The objectives of this thesis are to evaluate infants for suitability as a trial population, 
review diagnostic considerations which include evaluating the chest radiograph and the role of non-
tuberculous mycobacteria. Finally, I look into the lessons learnt from the development of a TB vaccine 
trial site. These objectives are explained in more detail at the end of the introduction.
Pathogenesis of Tuberculosis
The causative agent of Tuberculosis is Mycobacterium tuberculosis complex (MTBC), mainly trans-
mitted from person to person by droplets. Rarely, oral transmission occurs via unpasteurized milk. 
Thereafter, the course of the infection and disease is highly variable and to date, largely unpredictable. 
This is surprising, since MTBC has co-existed with man for millennia. In some individuals, certain 
immune mechanisms clear the infection before there is evidence of sensitization of adaptive immunity 
and these individuals can be resistant to TB infection (1-3). An unknown proportion of exposed 
persons develop latent or persistent infection (LTBI), defined as positive Tuberculin Skin Test (TST) 
or Interferon Gamma Release Assays (IGRAs) in the absence of clinical signs and symptoms of disease. 
It is estimated that about 1.7 billion individuals presently fall in this category (4). Of these, about 
10% among those who are HIV uninfected will develop active disease in their lifetime. In some other 
individuals, infection progresses to disease, but they remain asymptomatic and capable of transmission 
(5). A minority develop clinically apparent disease with evidence of progressive disease in body organs 
plus microbiological confirmation. The incubation period varies, but it is typically thought to range 
from about three months to two years, and after that disease is relatively infrequent (6).
Paediatric Tb
The course of paediatric TB is distinctly different from adult disease, particularly among young infants. 
TB is transmitted to infants through household contacts but mostly by exposures in the community 
(7). Studies from pre-chemotherapeutic era have attempted to quantify the natural history of the 
disease in children. After an infectious contact, an unknown proportion, but presumably higher than 
adults with similar exposure progress to primary infection. Of these, about 30-40% will progress to 
pulmonary disease after an incubation period of 3-8 weeks and 10-20% will develop disseminated 
disease one to three months after primary infection and approximately 50% of immunocompetent 
children will not develop disease (8). Infants therefore have a more severe course of disease with a 








Tuberculosis is the world’s deadliest infectious disease, measured by the numbers of people who die 
each year, surpassing HIV and malaria (9). About 1.3 million people died of the disease in 2017. Those 
HIV infected are disproportionately affected. At least 30% of deaths among HIV infected persons are 
attributable to TB. There were at least 10 million people who suffered from TB in 2017, enduring 
social and financial distress (10, 11).
Global differences in Tb burden
To optimize control strategies, it is important to map the disease and its determinants. There is con-
siderable asymmetry in the epidemic. Of 193 nations in the world, five (3%) are responsible for more 
than half of the global disease burden. They are Brazil, Russia, India, China and South Africa (BRICS), 
characterized by steady economic growth over the last 15 years, but low commensurate reductions in 
TB deaths and incidence. This is attributed to economic inequalities, with certain population segments 
in these nations living under squalid conditions, with poor access to health care. This maldistribution 
nullifies the value of economic growth in driving down per capita TB, as happened in some nations.
There is considerable diversity in the age, estimated incidence and affected populations across these 
nations. Brazil (63/100,000), Russia (60/100,000) and China (63/100,000) have low incidence per 
capita, while India (204/100,000) and South Africa (567/100,000) have high incidence (12). In Brazil 
and Russia, TB burden is driven by transmission hotspots among vulnerable groups such as homeless 
persons and prisoners (12). China’s disease rates are highest among the elderly who were sub-optimally 
treated prior to universal coverage of Directly Observed Therapy Short-course (DOTS) and set up of 
the National TB Program, resulting in high rates of reactivation (13). In India, patients seek care in the 
private sector first and frequently transition to the public sector, making it difficult for the program to 
track patients or assure quality of care. South Africa has the highest TB/HIV co-infection rates, and 
occupational hazards (mining) which drive incidence (14).
Tb trends
Globally, the decline of incidence by 1.5% per year, observed over the last decade, will not achieve 
a world with ‘zero deaths, disease and suffering due to TB by 2050’as envisioned by the STOP TB 
Partnership (14). The most recent targets envision a 95% reduction in TB mortality and incidence 
compared to the baseline period of 2015 (14). The most cost-effective long term solution for any 
infectious disease epidemic is effective vaccination (15, 16). This has been observed in cervical cancer 
(17, 18), polio (19), small pox, pneumonia (20). The discovery, development and rapid uptake of new 
interventions including a new TB vaccine are essential to the realization of a world free of TB (14).
The need for a new Tb vaccine: bacille calmette-Guérin (bcG)
The only licensed TB vaccine has been administered for about a century (21). Its efficacy and cost-
effectiveness against severe and disseminated forms of TB has been demonstrated (22). Protection 








25) and only in one study lasted fifty years (26). The lack of consistent, durable protective efficacy 
against the most transmissible form of disease threatens all control efforts. The reasons for this, as well 
as BCG’s exact mechanisms and correlates of protection are poorly understood.
factors linked to bcG (in)efficacy
Presently, the diversity of BCG strains, age at vaccination, exposure to environmental mycobacteria 
and the route of BCG administration are all thought to influence BCG efficacy.
BCG strain
After development of BCG from a cow isolate in 1921, sub-cultures in various laboratories over time 
led to differences in BCG genotype and phenotype (27). Studies in mice have shown the strains 
have varying capacity to evoke delayed type hypersensitivity, T-cell cytotoxicity and proliferation (28). 
Strain specific differences in immune response and reactogenicity have also been shown in humans 
(29). However, whether strains affect vaccine efficacy in humans has not been demonstrated in head to 
head comparisons in clinical trials. This could suggest that apparent variances in immunogenicity do 
not correlate with protection (30).
Age at vaccination and revaccination
BCG is a neonatal vaccine administered intradermal. Administration at birth is supported by data 
showing BCG efficacy is highest when administered to unexposed (TST negative individuals), and 
those with low sensitivity to Non Tuberculous Mycobacteria (NTMs) (30), both conditions are as-
sumed to be present in the early neonatal period. Additionally, BCG has beneficial off-target effects. 
They include promoting survival among low birth weight newborns, reducing all-cause mortality 
and infections in the neonatal period (31, 32) and improving heterologous Th1 responses to Tetanus 
Toxoid and polioviruses (31).
There have been concerns that new-born immunity is underdeveloped and could contribute to vac-
cine failure. When vaccination was deferred to 5-10 weeks of age, higher cytokine and T-cell responses 
were observed relative to neonatal vaccination (33, 34). It is not clear whether delayed vaccination 
translates to protective efficacy.
Delaying initial BCG vaccination to children aged 7-14 years with unknown TST status had mod-
est (25%) efficacy against PTB (35). Boosting is a strategy to counter waning immune protection 
conferred by previous vaccination. Hence, the observed rise of TB incidence at the inset of adolescence 
ends the ‘golden age’ of lowest TB incidence. This led to the trial of BCG revaccination in the pre-
adolescent period. However, this showed no efficacy (36). The authors conjectured that high helminth 
prevalence (37) may have reduced BCG efficacy in this instance. Notably, the inefficacy was present 
across all case definitions of TB. However, in the absence of Mantoux testing in the trial, some infected 







Immune interference by NTMs
Contrary to long held dogma, the sterility of the lungs in normal physiology has been shown to be false 
(39). The lungs, like the gut, has a diverse microbiome, sources of which include micro-aspirations 
from upper respiratory tract, or in inhaled air (40). NTM species have been detected in human oral 
cavity and upper respiratory tract microbiomes in healthy subjects (41). They are likely critical for 
immune fitness and resistance to TB (42). Further, it has been speculated that high prevalence of NTM 
sensitization accounts for poor BCG efficacy in the tropics. This is mediated through cross reactive 
immune responses by masking (inducing an immune response to which BCG cannot improve on) 
or blocking (induction of a cross-reactive immune response, leading to non-replication of BCG and 
hence its inefficacy) (43). As such, they could be responsible for unquantified heterogeneity in vaccine 
responses among individuals. The species, incidence in sputum and clinical relevance of NTMs among 
BCG vaccinated infants in most high burden countries is unknown and will be reviewed in this thesis.
Route of administration
A large trial among South African infants found no differences in efficacy between the conventional 
intradermal versus sub-cutaneous BCG administration (44). Intranasal administered BCG has been 
tested in mice to mimic natural infection, with better protection (45, 46). No similar human trials 
have been conducted.
Trial design, endpoints & sample sizes
The BCG replacement vaccine, VPM1002 (www.prime-vaccine.eu) and other promising vaccine 
candidates (47, 48) are likely to progress to Phase III trials. In order to efficiently conduct these studies, 
reliable incidence estimates and cohort characterization are needed for sample size calculations, to in-
form trial design, selection of diagnostic tools and choice of endpoints as well as the target population.
selection of target population
Traditionally, infants have been the natural target for new TB vaccines, since most vaccines are ad-
ministered to them. BCG also has variety of beneficial target and off target effects (49, 50), which has 
ethical implications for the control arm in future trials. To optimize the limited resources available 
for TB vaccine development, numerous modelling studies have been conducted to identify the most 
appropriate target population, with conflicting results (51-55). Below I briefly review the arguments 
for neonatal vaccines. Thereafter, I also look at modelling studies which attempt to predict impact or 
cost-effectiveness of vaccinating neonates versus adults/adolescents versus mass vaccinations.
Neonatal Tb vaccines
Conventional approaches to vaccination have failed to eliminate TB. As such the utility of neonates 
as a target population, must be reviewed against morbidity and mortality data as well as the potential 











Childhood TB has been neglected by health programs. Children are considered of less public health 
import in disease transmission, as they frequently have pauci-bacillary disease. In addition, making 
the diagnosis is challenging. Signs and symptoms can be non-specific and usually associated with con-
founding co-morbidities such as acute pneumonia, HIV and undernutrition. Further, diagnostic aids 
such as sputum culture or GeneXpert, IGRAs, TSTs, expert radiograph assessment are either absent in 
high burden settings or lack sensitivity/specificity (56). There are also problems with under-reporting 
of confirmed pediatric cases to National TB Programs (57). Moreover, the lack of age disaggregated 
reports masks the high susceptibility of young children.
Inaccurate TB incidence estimates
The dearth of accurate TB incidence data also hampers design of interventional studies. Cohort studies 
deploying comprehensive diagnostic and follow up methods are few, due to the large sample sizes 
required (58, 59). Recently modelling studies have attempted to estimate the burden. Paediatric TB 
apparently contributes substantial fraction of the total global TB burden. Specifically, young children 
under five years bear more than half of the total incidence burden in children (60). Since modelling 
studies have inherent limitations (60), and program data are unreliable, cohort studies that systemati-
cally determine infant TB incidence are needed.
childhood Tb mortality
Given the paucity of incident data, non-specificity of signs and symptoms, co-existing lung pathologies 
and co-morbidities, it is possible an appreciable number of cases are missed. This has been confirmed 
by post-mortem studies (61, 62). What would be the case fatality rate of undiagnosed and therefore 
untreated disease? From the pre-chemotherapeutic era, at least 20% of children with untreated TB 
died from the disease within one year (63), with the majority of the deaths occurring among infants 
and toddlers. Not only is this is alarmingly high even compared to adults (64), it shows how fatal 
undiagnosed infant TB is and it is likely a top ten leading cause of early childhood mortality (65). 
Therefore, young children have a high unmet need for a new effective vaccine and constitute a top 
priority population.
Feasibility of a pre-infection vaccine
Neonates are presumed to be uninfected with TB. They are therefore targeted for pre-infection vac-
cines, which seek to prevent onset of TB infection and halt disease progression.
Simple versus complex pathogens: A question remains whether a pre-infection vaccine is even 
feasible? With simple pathogens, for example viruses, disease incidence is a function of infection. 
Hence, halving infection rates for example by vaccination, halves the disease incidence rates. This is 
not necessarily true for TB since MTBC has a complex pathogenic process, where infection often does 







are also infected persons who also advance quickly to disease. Pre-infection vaccines would act on such 
susceptible persons who rapidly progress to disease for example infants (52).
Immunological precedence: There is some evidence BCG prevents infection in neonates, albeit from 
non-randomized studies (66). Recently, a trial of BCG vs H4IC31 vs placebo showed both vaccines 
incapable of preventing initial QFT conversion among QFT negative adolescents (48). Nevertheless, 
in natural infections, after MTBC exposure, it takes about six weeks to establish CD4 T cell responses, 
providing a window for vaccine induced immunity to combat MTBC evasion strategies, clearing the 
pathogen and preventing persistence of infection (67). Natural history studies show some individuals 
to be persistently TST/IGRA negative despite continued exposure (68). Hence, it appears that preven-
tion of infection vaccines for neonates could have immunological precedence.
Modelling studies in selecting the target trial population
Pre-infection vaccines (Prevention of Infection/PoI)
Modelling studies show pre-infection vaccines targeting TB unexposed neonates would substantially 
reduce the burden of new infections. This effect would increase over time. On the other hand, post-
exposure vaccines, targeting adults/adolescents would only minimally reduce the burden of new 
infections, and this effect would diminish over time (52).
Post-exposure vaccines (Prevention of Disease/PoD)
Modelling studies support greater and more rapid impact of adolescent/adult targeted prevention of 
disease vaccines in reducing the new number of cases of disease, over neonatal pre-exposure vaccines 
(51-53). Since infants do not transmit disease and it would be about 10-20 years before they are 
at increased risk of transmissible disease, a similar lag is expected before neonatal vaccination can 
impact the TB epidemic (54, 69). Further, economic evaluation models shows vaccinating adults to be 
remarkably cost effective (51). Recently released results of the phase IIb trial of M72/AS01E vs placebo 
in adults with LTBI showed 49.7% efficacy in preventing disease.
cONclusION
Modelling studies have value in conceptualizing multiple scenarios of vaccine coverage, efficacy, dura-
tion of protection and secular factors that affect disease epidemiology. They have inherent limitations 
which I describe below. Secondly, modelling studies are inconclusive on pre vs post-exposure vac-
cination. Some authors found neither pre nor post-exposure vaccines would reduce high incidence 
epidemics due to the complex pathogenic process of TB (52). A systematic review of 23 mathematical 
models exploring the potential impact of TB vaccines considered factors that would explain the incon-









a. External factors and geographical bias: Most models are based on an Asia like epidemic, driven by 
reactivation disease. Majority exclude Sub-Saharan Africa, where disease is driven by new infec-
tions (70, 71). If the rate of treatment of active disease would increase as envisioned in the present 
strategy (14), infections and thereby disease would decline, decreasing the relative impact of a 
pre-exposure vaccine in Asia like epidemics. Whereas a post-exposure vaccine would be found 
more useful in settings where reactivation disease drives the epidemic such as Asia (72).
b. The prevailing rates of LTBI: As few models report the LTBI rates used, it is difficult to assess 
comparative numbers of people most likely to benefit from post-exposure over pre-exposure vac-
cines (21).
c. HIV and Anti-Retroviral therapy status is largely ignored: It impacts longevity and probability of 
disease, vaccine efficacy (52, 54).
d. Availability of vaccination platforms and vaccine hesitance in adults is assumed in computing vac-
cine coverage. Vaccine hesitance is one of the top 10 global threats (73). There are few studies that 
have investigated the feasibility and acceptability of an adult TB vaccine. Developing a vaccination 
platform in most high burden countries will be costly and require complex logistical operations 
for health systems which are underfunded and burdened by providing care. This could undermine 
cost-effectiveness of an adult vaccine.
Diagnostic and endpoint considerations
Endpoints
In addition to identifying the target population, selection of endpoints also determine efficacy, as well 
as trial cost and duration. Non-microbiologically confirmed TB (Clinical TB) endpoints have been 
shown to undermine vaccine efficacy, given the vaccine is not designed to prevent non-TB respiratory 
ailments. The results of the M72/ASO1E vaccine trial confirmed this. Vaccine efficacy diminished 
proportional to the diagnostic distance from culture and molecular confirmation (47). However, when 
successful vaccine candidates move to efficacy trials, the relative rarity of incident TB necessitates 
sample sizes of tens of thousands of persons. To mitigate the risks of failure of a candidate after such 
a colossal investment, target vaccine profiles have been redefined to achieve lower threshold, ‘proof of 
concept’ end-points, namely: Prevention of Infection (initial or sustained IGRA conversion); Preven-
tion of Disease (POD); Prevention of Recurrence (PoR) and therapeutic vaccines (67).
Endpoints: Prevention of infection endpoints.
Prevention of infection endpoints require significantly lower sample sizes (48, 67) and shorter dura-
tions of follow up as the incidence of latent infection is greater than disease in high burden countries. 
Hence efficacy in PoI acts as surrogate and potential proof of efficacy against disease and can be needed 







Endpoints: Prevention of disease
Despite the attraction of PoI vaccines, PoD is really the most clinically meaningful end-point. Most 
latently infected persons have a low probability of progressing to disease, and further, prevention of 
initial or sustained QFT conversion, may not translate to PoD. Ultimately PoD trials are inevitable.
Chest radiograph (CXR)
Composite endpoints that include chest radiograph assessments have been used to define TB disease 
in trials. It is an invaluable adjunct of diagnosis. Nevertheless, it is fraught with risks. Most patients 
do not have classical radiological features (74), and the co-existence of multiple lung pathogens and 
co-morbidities among young children with TB confound the radiological diagnosis. For example, a 
comparison of radiological findings between severely under-nourished children with confirmed TB 
and those without, found no differences (75). Also a post-mortem study between the ante mortem 
radiographs of HIV infected and uninfected children found no difference in radiologic findings (76). 
Nevertheless, the specificity and reproducibility can be improved by using expert adjudication of 
radiographs.
Practical considerations: Site selection and development
Licensure trials for new PoI and PoD vaccines are likely to occur in high TB incidence countries. Most 
such settings lack the requisite clinical trial infrastructure and experience in conducting large studies. 
Infant mortality also tends to be high which can further undermine case ascertainment if there are 
numerous early deaths due to unrelated causes. Hence, large cohort studies deploying comprehensive 
diagnostic methods were needed to obtain incidence and mortality estimates.
Trial site description-Western Kenya
Outside of the BRICS countries, there are 25 other high burden countries, one of which is Kenya. The 
estimated prevalence of TB disease is 558/100,000 and about only half of those with the disease are 
treated (77).The estimated incidence is 319/100,000, with HIV co-infection rates of 29% (12). TB 
rates are highest among males and those aged between 25 and 30 years (77). The exact drivers of the 
epidemic have not been well characterized. The study site described in this thesis was set up following 
receipt of funding and co-funding from a consortium of partners to create capacity to conduct TB 
vaccine trials in 2007. A large complement of data and laboratory staff, nurses, pharmacists, doctors 
and clinical officers received training and practical experience in trial related procedures.
In 2009, a large cohort of neonates were enrolled to determine TB incidence (Infant Cohort Study). 
It was a landmark study that had not been done previously in the country nor has it been replicated 
since in Kenya. The cost investment of such studies is prohibitively high and therefore the lessons 









Overall, the aim of this thesis was to determine the suitability of infants as a trial population and 
inform diagnostic considerations for future TB vaccine trials. This included documenting the practical 
experience of site set up and trial implementation as well as the lessons for TB vaccine development. 
These questions are addressed in TB studies particularly among infants.
The specific objectives were:
To evaluate infants for suitability as a target population
- To assess TB incidence, post-neonatal mortality and cohort retention among infants.
Diagnostic considerations
- To evaluate the chest radiograph (CXR) for its suitability as an endpoint for infant trials where 
paucibacillary disease is most frequent.
- To determine the clinical relevance of non-tuberculous mycobacteria isolated in sputum, given 
their ubiquity and indistinguishable case presentation to TB disease.
lessons from site development and for the Tb vaccine pipeline
- To reflect on the lessons learnt in building a new TB vaccine site and review the TB vaccine 
development pipeline in the context of the Ebola virus outbreak.
OuTlINe Of ThesIs
chapter 2 describes the incidence of TB disease among infants, as a potential trial population. This 
chapter differentiates incident TB based on whether it is microbiologically confirmed or not and 
calculates the sensitivity of sample sizes for each case definition to determine the suitability of infants 
as a target population. We also examine retention, which also influences sample size. chapter 3. High 
infant mortality is an important cohort characteristic of most high incidence countries, it undermines 
the ability to detect endpoints. In such settings, how much mortality can we anticipate in infant 
trials, and how much of it is due to background morbidity? This section determines the post-neonatal 
mortality in the study area, also the determinants and causes of mortality. chapter 4 examines the 
diagnostic utility of the chest radiograph for defining non-microbiologically confirmed TB endpoints. 
What is the inter-rater agreement of expert and non-expert readers in assessing radiographs for con-
sistency with TB? The implications of including the expert readings of the chest radiograph on TB 
incidence, vaccine efficacy and sample size calculations will be reviewed. chapter 5 defines the species, 
clinical relevance, diagnostic difficulties and incidence of the ubiquitous non-tuberculous mycobac-
teria among infants with presumptive TB. chapter 6. Phase IIb and III TB vaccine trials require 







expertise are needed in high incidence countries. This chapter reviews the challenges and opportunities 
of developing a TB vaccine site against the backdrop of the momentous breakthrough that was the 
demonstration of efficacy of the Ebola virus vaccine. In the discussion, I summarize our findings in 
relation to questions raised in this thesis, contextualize our results and provide future perspectives in 
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background | Infants are a target population for new tuberculosis (TB) vaccines. TB incidence esti-
mates are needed to guide the design of trials. Objectives: To determine the TB incidence and cohort 
retention among young children using comprehensive diagnostic methods in a high burden area.
Methods | Infants 0-42 days were enrolled. Through four monthly follow up and unscheduled (sick) 
visits up to the age of two years, infants with Presumptive TB based on a history of contact, TB 
symptoms or pre-determined hospitalization criteria were admitted to a case verification ward. Two 
induced sputa and gastric aspirates were collected for culture and GeneXpert. Mantoux and HIV 
tests were done. Clinical management was based on the Keith Edwards Score (KE Score). Cases were 
classified into microbiologically confirmed or radiological, diagnosed by blinded expert assessment. 
Cox regression was used to identify risk factors for incident TB and study retention.
Results | Of 2900 infants enrolled, 927 (32%) developed presumptive TB. Sixty-nine TB cases were 
diagnosed (bacteriological and radiological). All TB incidence was 2/100 person-years of observation 
(pyo) (95% CI 1.65, 2.65). Nine were bacteriological cases, incidence 0.3/100 pyo. Radiological TB 
incidence was 1.82/100 pyo. Bacteriological TB was associated with infant HIV infection and higher 
KE scores. Completeness of 4 month vaccinations and HIV infection were positively associated with 
retention.
conclusion | TB incidence was high. An all TB endpoint would require a sample size of a few thou-




































Pulmonary tuberculosis (TB) is an important public health problem worldwide. With 10 million new 
cases of TB and 1.3 million deaths in 2017 (1). In Kenya, a recent national prevalence survey, utilizing 
newer tools such as the GeneXpert showed higher rates than previously reported (2). The End TB 
Strategy of WHO emphasizes diagnosis and treatment of TB patients, as well as the need for research on 
methods to prevent TB, including new vaccines for high risk populations such as adolescents (3) and in-
fants (4, 5). Childhood tuberculosis, while not easily transmissible, has higher morbidity and mortality 
risk (6, 7) for both HIV infected and uninfected individuals (8). It is also harder to accurately detect (7, 
9). Young children are unable to expectorate adequately, and more invasive methods are required that 
include nasopharyngeal and gastric aspirates, or induced sputa. The necessary skills and infrastructure 
are hardly available in most primary care settings (10, 11). When sputum culture or GeneXpert are 
available, sensitivity is somewhat low as young children often have paucibacillary disease (7).
In many settings, clinical and radiological criteria form the backbone of diagnosis. Clinical criteria 
include a composite score chart (12, 13) ranking for history of contact or evidence of exposure to 
TB by Mantoux tests or their equivalent, protracted classical TB symptoms, failure to thrive with or 
without a suggestive chest radiograph. The criteria have poor specificity for TB in HIV infected infants 
who will tend to have prolonged cough, night sweats or weight loss due to other co-morbidities. (11, 
13, 14). Also, children with respiratory illnesses frequently have multiple infections, chiefly bacterial, 
complicating the clinical picture (8, 11, 15). Chest Computed tomography (CT), the gold standard 
for detection of mediastinal lymphadenopathy, the radiological hallmark of primary tuberculosis (16), 
is unscalable, costly and associated with high radiation exposure. Chest radiographs (CXR) are more 
readily available in TB endemic settings. It has been noted that CXR readings have poor specific-
ity among non-experts or clinicians with basic training (17) and classical diagnostic features are less 
frequently observed than among adults (18). Having a chest radiograph compatible with TB, doubled 
the odds of culture positivity among children (19). The CXR therefore seems a valuable addition to 
the paediatric TB detection armoury.
In most low and middle income countries where TB is endemic, extensive neonatal vaccination 
programs using Bacille Calmette-Guérin (BCG), have reportedly reduced the incidence of severe 
childhood TB including TB meningitis, and miliary TB (20) (21). Nevertheless, several trials for new 
infant TB vaccines have advanced in the last decade (22-24) in recognition of BCG’s variable efficacy 
against pulmonary TB (25) and evidence that protection wanes (26). We sought to conduct a large 
cohort study, utilizing more comprehensive case finding and diagnostic methods to determine TB 
incidence among infants in Western Kenya, in order to inform sample size calculations, mortality 
patterns and estimates ahead of a trial of new TB vaccine candidates. A large portion of the study area 
is covered by a Health and Demographic Surveillance System (HDSS), tracking births, deaths, and 
migration. The majority of the deliveries occur at home (27). The study area has a high morbidity 
burden from respiratory diseases (28-30), acute and chronic undernutrition (31, 32) Birth rates and 








The Infant Cohort Study was conducted from 2009 to 2011, in the Karemo, Gem and Boro Divisions 
in Siaya County, Western Kenya.
Recruitment
Home births were notified via traditional birth attendants, while health facility births were notified 
by the respective staff to the recruitment supervisor. Due to the health and demographic surveillance 
system, all home births were notified within 6 weeks of birth to the study staff. Infants aged zero to 42 
days, and weighing ≥1700g were eligible, if they were expected to remain in the study area for more 
than two years and had been in the area since birth or for at least one month. Low birth weight babies 
were excluded due to their higher risk of mortality (would take away potential TB disease endpoints). 
Families planning to out migrate from the study area would make it impossible to ascertain TB disease 
endpoints and increase loss to follow up. Following notification, a study nurse was dispatched to review 
the infant for eligibility, obtain informed consent, take anthropometric measures, and provide BCG 
vaccination (Danish Strain, Staten’s Serum Institute).
Study follow up visits took place at health facilities closest to the parents/guardians as follows; at six 
weeks of age for HIV DNA PCR testing (AMPLICOR COBAS), thereafter four monthly for one to 
two years depending on time of enrolment. During follow up visits, parents were asked about history 
of TB contact, TB symptoms in their infants and history of hospitalization. Participants who were 
unable to come to health facilities had home visits. Loss to follow up (LTFU) was defined as unknown 
status after three unsuccessful tracing attempts by study close out. Free ancillary care was provided at 
the study clinic, with hospitalization at the Siaya County Hospital. HIV infected participants were 
referred for care and anti-retroviral therapy (ART) at the HIV comprehensive care clinic.
Identification of presumptive Tb.
Due to the non-specific presentation of infant TB, a broad criteria for presumptive TB was defined 
in the protocol for study purposes. At scheduled or ancillary unscheduled visits infants meeting the 
following criteria were considered to have presumptive TB: parental report of household TB contact or 
TB symptoms (cough for two weeks or more, night sweats for two weeks or more, fever for two weeks 
or more or undernutrition (underweight for age)) or a history of hospitalization with severe lower 
respiratory tract infections, meningitis, HIV/AIDS, or malnutrition. Health record surveillance of TB 
registers and the laboratories in the region was conducted to identify if notified TB cases were contacts 
of study participants. This was operationalized by searching the HDSS database using the case name 
and location and matching that to our study participants’ HDSS address.
Tb investigations
Participants with presumptive TB were admitted to a case verification ward (CVW) for collection of 



































using 2 Tuberculin Units PPD RT23 (Staten Serum, Denmark), DNA PCR or HIV Antibody test-
ing, and antero-posterior and lateral digital radiographs (CXR). Clinicians evaluated the radiographs 
during admission. Anthropometric measurements (middle upper arm circumference and weight for 
age) and clinical ranking using the Keith Edward (KE) Score chart for TB was done. TB treatment was 
initiated if the KE score was ≥7 or if the CXR was consistent with TB or if TB was microbiologically 
confirmed. Participants who started TB treatment with a KE score ≥7 but a negative CXR for TB or 
not microbiologically confirmed were not considered cases for this study.
Sputum samples underwent liquid and solid culture by Mycobacterial Growth Indicator Tube 
(MGIT) and Lowenstein Jensen (LJ) media. Thereafter, speciation for positive cultures was done using 
Capilia (FIND and Tauns co. Ltd) or GenoType assay (Hain Diagnostika, Nehren, Germany). Later, 
when GeneXpert MTB/RIF became available, additional sputum testing was performed from frozen 
stored sputum pellets. No drug susceptibility testing was done.
case Definitions
TB cases were classified into bacteriologically confirmed and radiographically diagnosed cases. Bac-
teriologically confirmed were microbiologically confirmed. An expert panel comprising a paediatric 
pulmonologist and radiologist performed blinded reviews of CXRs using a standard form developed 
for TB vaccine trials sites through consensus (17). Any radiograph classified as consistent with TB was 
defined as radiographically diagnosed TB. Due to subjective assessment of clinical criteria, radiological 
and bacteriological criteria are presented in this paper to provide a more objective assessment of actual 
cases that would be end-points in a future TB vaccine trial and that are more stringent. Clinical criteria 
are non-specific due to other prevalent co morbidities like HIV, malnutrition and failure to thrive. 
A positive Mantoux test was an induration of ≥ 10mm (or ≥5mm in the presence of severe acute 
malnutrition or HIV infection).
statistical Methods
Electronic case report forms were used. Data was analysed using STATA 13 (STATA corp California). 
We defined enrolment weight as low if it was <2500g and normal at ≥2500g. Nutritional status was 
classified based on mid-upper arm circumference for infants older than 6 months or weight for age 
WHO Z scores for those less than 6 months. Person time was calculated from enrolment to the last 
study contact in a scheduled or unscheduled visit or death whichever was last or TB disease diagnosis. 
Radiographically cases diagnosed by experts were censored at the date of CXR. Incident TB was com-
puted for bacteriologically confirmed and all TB by dividing the number of cases by the total person 
time. Cox proportional hazards was used to compare those who became TB cases versus the rest of the 
study population, identify risk factors for TB and study retention. Vaccination status at four months of 
follow up, when Pentavalent III has been given was tested as a potential predictor of retention.
Factors that were statistically significant during univariate analysis were further included in a multi-
variate Cox regression model to adjust for multiple factors to determine those remaining significant risk 







of bacteriologically confi rmed and radiographically diagnosed TB. Th ese independent variables were 
included: TST, KE Score, nutritional status, history of household contact, infant HIV and reason for 
TB investigations.
Frequency of ancillary care visits (sick visits) and hospitalization between zero and four months were 
considered potential risk factors for incident TB at follow up.
ResulTs
Tb incidence
Of 2900 infants enrolled, 196 (6.8%), moved out of the study area upon enrolment. A total of 2704 
infants were followed up for TB incidence, with 3298 person years of follow up (pyo). (Figure 1).
Mean follow up time was 1.14 pyo (median 1.3 pyo). Th ere were 205 (7%) total deaths, of whom 
26/205 (13%) were known to be HIV infected. About a third of the deaths were in the neonatal 
period, thereafter most identifi able immediate causes of death were due to severe dehydration and 
acute respiratory ailments (33).
We identifi ed 927/2900 (32%) as presumptive TB cases, of these we investigated 737/927 (80%) 
and found 69 individuals to have TB based on microbiological confi rmation or radiological criteria. 
Th e incidence rate of all TB was 2.0/100 pyo (95% CI 1.65, 2.65). Th ere were nine bacteriologically 
confi rmed TB cases, incidence rate was 0.3 per 100 pyo (95% CI 0.1, 0.5) and the incidence of 
radiological TB was 1.82/100 pyo. In addition, sixty cases had CXRs consistent with TB. Th e experts 
figure 1 | Flow diagram of the selection of infants for incidence follow-up and the number, who are deceased, 



































identified 64/69 all TB cases, of which they agreed on only seven. One of the experts identified 43/60 
radiographically diagnosed cases and 4/9 bacteriologically confirmed on CXR. The other expert identi-
fied 21/60 radiographically diagnosed cases and 3/9 bacteriologically confirmed on CXR.
sociodemographic predictors of Tb
There were no differences in demographic (sex, maternal age) socioeconomic indicators (maternal 
occupation) between TB cases and the rest of the cohort at baseline. There were also no significant 
differences in infant enrolment weight and maternal HIV status between the groups. However, the 
incidence of TB was higher in those with HIV (p=0.0004) and those reporting a household contact 
at baseline (p=0.04). TB incidence was lower among mothers who attended antenatal care visits 
(p=0.04). (Table 1).
comparative clinical characteristics of Tb cases
We compared the clinical characteristics of bacteriologically confirmed and radiological cases. Com-
pared with cases identified with radiology, bacteriologically confirmed TB patients had more often a 
KE score>=7 (OR 17.0, 95% CI 2.78, 104), were more often TST positive (OR 10.8, 95% CI 2.16, 
54.4), and reported more frequently a history of TB contact (OR 6.13, 95% CI 1.10, 34.2). There 
were no other significant differences in clinical characteristics. (Table 2)
Table 1 | Baseline characteristics of TB cases versus study population and univariate HR for incident TB
baseline Variable Tb case n=69 pyrs hR (95% cI)
Gender Male 38 1610 1.17 (0.73, 1.88)
Female 31 1688 1*
Place of birth Home 49 2147 1.29 (0.77, 2.18)
Health Facility 20 1131 1*
Maternal hIV Positive 9 2766 0.87 (0.43, 1.75)
Negative 60 474 1*
Infant hIV status Negative 62 3228 1*
Positive 7 69 5.81 (2.65, 12.7)
Maternal age (years) <19 16 635 1*
20-29 39 1722 0.86 (0.48, 1.55)
>29 14 941 0.56 (0.27, 1.15)
aNc attendance Yes 57 2911 0.53 (0.28, 0.98)
No 12 328 1*
enrolment weight (grams) 1700-<2500 4 239 0.79 (0.29, 2.16)
>=2500 65 3058 1*
household contact Yes 9 203 2.11 (1.05, 4.29)
No 60 3095 1*
Maternal occupation Unemployed/farmer 63 2872 1*
Business/Salaried 6 426 0.61 (0.26, 1.42)







Risk factors for incident Tb
In univariate comparisons, infant HIV infection, two or more hospitalisations, one or more sick visits 
and household TB contact at baseline were risk factors for incident TB. We adjusted for these variables 
and found infant HIV infection increased the risk of incident TB, adjusted Hazards Ratio (aHR) 
4.71 (95% CI 2.13, 10.4)]. Two or more hospitalisations by 4 months of age also increased risk, 
adjusted Hazard Ratio (aHR) 2.10 (95% CI 1.09, 4.03)] as did multiple sick visits, adjusted Hazard 
Ratio (aHR) 2.17 (95% CI 1.12, 4.22)]. Household TB contact was not a significant predictor in the 
adjusted model. (Table 3)
loss to follow up
One year loss to follow-up was lower with increasing maternal age in both the univariate and multi-
variate analysis; adjusted Hazard Ratio (aHR) 0.89 (95% CI 0.79, 1.00). Complete vaccination status 
measured by proportion who had received all required vaccinations by four months per the Kenya 
Expanded Immunization Program (KEPI) was associated with lower loss to follow-up; adjusted Hazard 
Ratio (aHR) 0.44 (95% CI 0.39, 0.49). Employed mothers or those in business had lower loss to fol-
low up compared to unemployed; adjusted Hazard Ratio (aHR) 0.73 (95% CI 0.64, 0.84)]. (Table 4)
Table 2 | Comparing clinical characteristics of definite and chest radiograph TB cases
characteristic Definite Tb N=9 cXR Tb N=60 hR (95% cI)
TsT Negative 5 52 1*
Positive 3 8 10.8 (2.16, 54.4)
Missing 1
Ke score^ category <7 4 51 1*
≥7 4 3 17.0 (2.78, 104)
Missing 1 6
Nutrition Normal 2 7 1*
At risk 2 10 0.70 (0.08, 6.22)
Moderate malnutrition 4 33 0.42 (0.07, 2.79)
Severe malnutrition 1 10 0.35 (0.03, 4.65)
history of Tb contact No 4 49 1*
Yes 3 6 6.13 (1.10, 34.2)
Missing 2 5
Reason for investigation Contact 1 4 1*
Hospitalization 3 36 0.33 (0.03, 4.01)
Symptoms 3 14 0.86 (0.07, 10.7)
Missing 2 6
Infant hIV status Negative 6 50 1*
Negative (exposed) 2 4 4.17 (0.63, 27.8)
Positive 1 6 1.39 (0.14, 13.6)
* 1 = set as the reference














































HIV status Negative 56 2409 2793 1* 1*
Negative 
(exposed)








Nutrition Normal 9 376 442 1*








11 290 343 1.60
(0.66, 3.86)
Missing 209
Hospitalization 0 52 2521 2902 1* 1*








Sick visits by 4 
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0 visits 13 1311 1269 1* 1*








History of TB 
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No 60 2698 3095 1* 1*




Maternal age <19 16 619 635 1*
20-29 39 1494 1722 0.86
(0.48, 1.54)






63 2479 2872 1*
Business / 
salaried
6 352 426 0.61
2(0.26, 1.42)
Retained No 2 628 170 1*
Yes 67 2202 3127 1.10
(0.26, 4.62)







sample size requirements for vaccine trials in this population
We estimate based on our bacteriologically confirmed incidence rate a total of 24,321 infants in a 1:1 
randomization would need to be enrolled for both arms combined at an incidence rate of 0.3/ 100 pyo 
to demonstrate a 50% vaccine efficacy with 91 TB cases in the placebo arm and a 20% loss to follow 
up over 3 years. About half that number would be required with a vaccine of 70% efficacy. Conversely 
a total of one thousand four hundred and four infants would be needed for both arms combined to 
demonstrate a 50% vaccine efficacy given an all TB rate in the order of 2/ 100 pyo. (Table 5)
Table 4 | One year loss to follow up (LTFU) and factors associated with LTFU of prospectively followed up infants






Gender Male 220 1610 1*
Female 215 1688 1.01 (0.94, 1.11)
Place of Birth Home 181 1131 1* 1*
Health Facility 252 2147 1.04 (0.96, 1.14) 0.80 (0.60, 1.09)
Infant HIV status Negative 395 2793 1* 1*
Negative exposed 32 436 0.98 (0.87, 1.10) 0.98 (0.86, 1.12)
Positive 8 69 1.53 (1.20, 1.96) 1.41 (1.06, 1.89)
Maternal Age <19 149 635 1* 1*
20-29 232 1722 0.86 (0.77, 0.96) 0.89 (0.79, 1.00)
>29 54 941 0.85 (0.75, 0.96) 0.89 (0.78, 1.02)
ANC attendance Yes 43 328 1*
No 387 2911 1.02 (0.89, 1.17)
Vaccination status incomplete 78 510 1* 1*
complete 97 2477 0.44 (0.39, 0.49) 0.44 (0.39, 0.49)
Maternal occupation Unemployed/ Farmer 378 2872 1* 1*
Business/Salaried 57 426 0.71 (0.62, 0.81) 0.73 (0.64, 0.84 )
* 1 = set as the reference
Table 5 | TB vaccine sample sizes
Presumed vaccine efficacy
50% 60% 70%















0.3/100 24.321 88 44 16.318 59 23 11.554 42 12
2.0/100 1.404 34 17 942 23 9 667 16 5




































Incidence of Tb and implications
We observed a high incidence of all TB among infants in Western Kenya in the order of of 2/100pyo. 
A much lower incidence of bacteriologically confirmed TB (0.28 per 100 pyo) was found. This is 
consistent with infant disease which is classically paucibacillary. It is higher than reported definite TB 
incidence in Mozambique, (0.14 per 100 pyo (34)) but lower than in the Western Cape, (1.2 per 100 
pyo (5)). A large number of participants were identified as having presumptive TB indicating a high 
morbidity burden that lead to TB suspicion. TB vaccine trials will need to formulate strategies to deal 
with this high morbidity burden in infant vaccine trial cohorts and provide the staff capacity needed 
to cope with the large number of TB investigations required. In addition, 20% of participants with 
presumptive TB were not investigated. The requirement for a 48 hour admission for TB investigations 
might have led some parents to decline investigations. Future studies need to offer flexibility including 
exploring day admissions and discharges for infants whose parents are unwilling to have overnight 
admissions. The missed investigations might have underestimated the burden of TB in this cohort.
case definitions
Our study utilized a chest radiographs (CXR) to define non-microbiologically confirmed TB. To be 
clear, these infants met clinical criteria for TB suspicion, therefore the CXR was a confirmatory tool, 
in the absence of microbiological confirmation. There are challenges related to the diagnosis of TB 
in children in regard to the use of CXRs which include; Identification and interpretation of CXR 
abnormalities are variable and often inconsistent (35), CXR parenchymal abnormalities in infants 
and young children with TB are not specific for TB but overlap with CXR abnormalities due to other 
lower respiratory tract infections (36) and CXR is less sensitive for detecting TB-related intrathoracic 
abnormalities than other imaging modalities (37). Despite the low agreement between the expert read-
ers, 3 out of 7 CXRs defined as consistent with TB were also culture confirmed indicating having more 
than one reader is key in identifying TB. One way to improve on the poor agreement between experts 
would be to require an additional criteria like latent TB infection, for definition of TB in addition to 
a CXR consistent with TB where the experts don’t agree. The study area has a high morbidity burden 
due to HIV, undernutrition and acute respiratory diseases (19, 27, 30, 31, 33). The limitations of a 
clinical score chart, namely low specificity and high sensitivity, leading to over-treatment have been 
documented (13, 14). The chest radiograph therefore was used for a viable case definition, in light of 
low sensitivity of microbiological methods. It has been shown that chest radiographs, are a significant 
correlate of culture confirmed TB in settings endemic for HIV and other co-morbidities (19, 38). 
Unfortunately, an intrinsic risk of this approach is the lack of specificity which would underestimate 
vaccine efficacy, given that new candidates are not geared toward prevention of non-TB respiratory 
ailments. As this study utilized blinded experts expected to have higher specificity compared to non-
expert clinicians (17), misclassification was minimized to the extent possible. This approach also 







Infant Tb diagnostics and alternative samples
There are currently limited options for TB diagnosis in young infants. Nasopharyngeal and stool 
samples could be non-invasive alternatives to induced sputum and gastric lavage. Nevertheless, when 
analysed using Gene Xpert, both have shown lower sensitivity in children compared to sputum (39-
41). The WHO has recommended the use of Xpert MTB/RIF over conventional microscopy and 
culture as the initial diagnostic test in all children suspected of having TB, while acknowledging the 
resource implications. IGRAs and commercial serology diagnostics tests are not recommended for use 
in infants regardless of their HIV status (42, 43). New diagnostic tools are needed. These must then be 
validated in very young children.
In an autopsy study of children with lung disease, undiagnosed TB was among the top three causes 
of death among HIV infected and uninfected children, supplementing data showing that definite 
TB alone could be an insensitive indicator of disease (8). Missed TB cases are found at autopsies (44, 
45), particularly among children (45, 46) in both low and high TB incidence settings. About 7% of 
the cohort died during the study; obtaining ethical approval and informed consent to include limited 
but targeted post mortem exams, would increase the number of end-points in a TB vaccine trial. One 
necropsy study showed an additional 25% of respiratory related deaths among hospitalized children 
were attributable to undiagnosed TB. This potential end-point has not been included in previous trials.
Risk factors
HIV infected infants had a two to ten-fold increased risk of TB disease. Unfortunately, most TB 
vaccine trials exclude this population for safety reasons. This is the population that most urgently needs 
a more efficacious TB vaccine. Frequent hospitalization and out-patient sick visits can be considered a 
marker of chronic morbidity. Patients with one or more sick visits and hospitalizations had more than 
one to four fold increased risk of TB. While it is possible that the sick visits increased the probability 
of TB detection, the higher frequency may also be an indication of underlying vulnerability to TB.
Tb vaccine trial sample sizes
Our study sought to determine incidence estimates for sample size calculations of hypothetical 
clinical trials. Due to reliability and validity concerns around TB diagnosis in young children; relying 
narrowly on bacteriologic confirmation of cases would necessitate exposure of tens of thousands of 
trial participants to an investigational product, depending on vaccine efficacy. Unfortunately, broad 
criteria that include radiographic and clinical cases might mean some non-cases are included, leading 
to underestimates of the efficacy of a vaccine candidate.
Including HIV infected infants who are more likely to develop TB, and also most likely to benefit 
from the protection of an efficacious vaccine, would minimize sample sizes considerably. However, 





































Critical to the success of any vaccine trial is retention of participants for end-point determination. 
A considerable proportion of study participants, exited the study area after enrolment (7%). Future 
studies must consider cultural norms where women migrate to other areas to give birth and return to 
their marital homes shortly after. This should be taken into consideration on deciding on inclusion 
and thus reduce loss to follow-up. Thereafter, the loss to follow-up was about 12% and this would 
need to be factored into sample size considerations. Factors of health seeking behaviour, particularly 
completeness of infant vaccination predicted retention. This suggests possible selection bias in case 
detection, as those who are lost to follow up, may have less favourable health seeking behaviour and 
therefore are less likely to be diagnosed with TB.
Increasing maternal age was positively associated with retention. Vaccine trials, can possibly deploy 
better strategies to retain younger mothers including targeting them for phone/home follow up to 
increase their retention. Our study population largely comprised children of peasant farmers and 
unemployed women, whereas those who were employed or running businesses were more likely to be 
retained. In consideration of this skew, such mothers might require off-site follow up such as home 
visits or provisions for comprehensive tracing when they out-migrate.
limitations
As the majority of TB is not microbiologically confirmed, alternative case definitions that use radio-
logical criteria were used. We diagnosed TB when any of the blinded experts considered the radiograph 
to be consistent with TB, however most clinical trials would only consider the radiographs where 
experts agreed to be a TB case. Low expert inter-rater agreement has been demonstrated (17). Since 
experts agreed on only seven infants as having TB, the low yield would be an additional limitation to 
overcome. With all cohort studies, loss to follow up may occur and this may have underestimated our 
TB incidence estimates. In addition, sputum samples were not tested further to exclude other viral or 
bacterial respiratory pathogens that could have similar radiological presentation, this could potentially 
overestimate TB incidence.
strengths
Our study is one of the first to reliably document TB rates among infants in Western Kenya. We de-
ployed expert readers to adjudicate on cases, as would be the case in a vaccine trial. We deployed CXRs 
to estimating the TB incidence, in consideration of the disease patterns in the study area as well as the 
diagnostic challenges. Therefore we consider the study findings to be generalizable to similar settings.
cONclusIONs
High TB incidence among young children in Western Kenya particularly among the HIV infected 







population is suitable for new TB vaccine trials. However, large sample sizes would be needed for phase 
III trials, given the low definite TB incidence. Inclusion of necropsy studies and radiological TB may 
increase the number of study end-points and reduce the sample sizes. Retention of young women and 
unvaccinated infants who may have a different risk of TB profile, requires deliberate design of such 
studies.
ethical approval
The protocol and informed consent forms were reviewed and approved by the KEMRI local and 
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Chapter 3
Predictors of post-neonatal mortality in 
Western Kenya: A cohort study
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Introduction: To determine the predictors of mortality in infants in Siaya, Western Kenya, ahead of 
novel Tuberculosis (TB) vaccine trials in the same population.
Methods: In a study to determine tuberculosis incidence, 2900 infants aged 0-45 days, weighing 
≥1700g were enrolled. Four monthly follow up visits were conducted for at least 12 months. HIV 
testing was done at six weeks of age. Free ancillary care was provided. Deaths were reported by parents, 
study staff and community workers. Cox proportional Hazard analysis was used to identify risk factors. 
The period of analysis commenced at six weeks old and was censored at 12 months of age.
Results: Included in the analysis were 2528 infants with 2020 person years of follow up (pyo). There 
were 117 deaths (4.6 %). The post-neonatal mortality rate was 58 (95% confidence interval (CI): 
48, 69) per 1000 pyo. In multivariate analysis, health facility births were protective against mortality 
(Hazard Ratio (HR) 0.54; 95% CI: 0.34, 0.84) and infant HIV infection at baseline was associ-
ated with increased mortality (HR 10.3; 95% CI: 6.40, 16.7). HIV uninfected infants born to HIV 
infected mothers had increased hazards of mortality (HR 1.73; 95% CI: 1.03, 2.90). Gender, weight 
at six weeks, maternal education and occupation were not significant predictors of mortality.
conclusion: Infant mortality was high and was associated with being born outside a health facil-
ity, maternal HIV infection and HIV infection of the infant. Measures to decrease mother to child 
transmission and other HIV control measures need to be strengthened further to see incremental 



































Strategies to reduce child deaths have been extensively studied [1-3]. Over the last two decades 
considerable progress has been made in averting thousands of child deaths [4]. This is attributable 
to improvements in socio-economic conditions and scale up of disease specific interventions such 
as use of insecticide- treated bed nets, oral rehydration therapy for diarrheal disease targeting the 
main causes of childhood deaths. In fact, Kenya has experienced reduction of infant mortality from 
77/1000 in 2003 [5] to 52/1000 live births in 2008 [6] and 39/1000 live births in 2014 [7]. Despite 
this considerable decline from high levels of mortality, it is a forty-fold higher probability of death 
compared to a child born in developed countries where the chances are less than one death in every 
one thousand live births [8]. Several studies have revealed various determinants of child mortality. 
Child spacing, birth order, maternal illiteracy, income disparities, rural versus urban residence, relative 
distance from health facilities have all been known to account for high child mortality [9-11]. These 
have been identified from cross-sectional studies such as national health and demographic surveys 
[1, 2]. Data from cohort studies have been less frequently employed although they might provide a 
better assessment of relationships between possible causal factors and mortality [12]. Further, due to 
close follow up in cohort studies, more information on proximal health variables may be available. 
We conducted a cohort study between June 2009 and September 2011 to determine what factors 
predicted infant mortality in Western Kenya. This was a preparatory study to obtain tuberculosis (TB) 
incidence estimates amongst infants in preparation for trialing novel TB vaccine candidates in the 
same population, with infant mortality as a secondary objective. Deaths that occur in the conduct of a 
clinical trial may be misattributed to the investigational agent if background mortality rates and causes 
are not clear. Excess mortality also implies missed end-points when they occur prematurely.
MeThODs
setting
The study area was predominantly rural in Karemo, Gem and Boro Divisions of Siaya County, West-
ern Kenya. The infant mortality rate at the time in this area was 110/1000 live births [13], more 
than double the national average. The area has a high prevalence of the HIV and TB syndemic, with 
perennial intense malarial transmission [13, 14]. About 80% of women deliver at home without the 
help of a skilled attendant [15, 16]. Subsistence farming is the main economic activity. Educational 
attainment of female population is low: 9.3% of women have some secondary education while 49.3% 
have some primary education. Siaya County is served by 31 dispensaries and health facilities, manned 
by nurses who provide vaccinations, antenatal care, contraception, and empiric treatment of basic 
ailments. Several of these facilities provide Anti-Retroviral Therapy at Patient Support Centres (PSCs). 
Hospitalizations mainly occur at the Siaya County Hospital. The proportion of low birth weight 








The target was to enrol a total of 2900 infants 0-45 days of age, between June 2009 and June 2010 
who were at least 1700g at enrolment. Follow up visits were carried out every four months for at 
least one year, maximum of two years depending on the time of enrolment. Participants enrolled 
earlier had a longer duration of follow up. Visits were conducted at a health facility of the parent’s 
choice or at home. To enrol infants, we received birth notifications from community health workers 
who frequently doubled as Traditional Birth Attendants (TBAs). Study nurses on motor bikes visited 
homes of interested potential participants. They obtained informed consent, took anthropometric 
measurements and administered BCG vaccine to those unvaccinated. Infants below 1700g at time 
of enrolment were excluded. At age six weeks, Deoxy-ribo-Nucleic Acid (DNA) Polymerase Chain 
Reaction (PCR) HIV testing (COBAS® HIV-1 Amplicor by ROCHE) was offered to all participants. 
Additional HIV testing was done as part of TB investigations for those with presumptive TB (at time 
of study were named TB suspects), during follow up and at study exit. Parents and participants who 
tested HIV positive, were referred to the Patient Support Centre for Anti-Retroviral Therapy (ART) 
initiation and care. A dedicated study nurse visited these participants to counsel on feeding options 
and encourage ART initiation.
Free ancillary care was provided at the study clinic. The study covered the cost of transport up to 5 
USD and hospitalizations at the Siaya County Hospital. Supplemental feeds provided by UNICEF 
to the hospital were also administered by the study nutritionist for participants who met the criteria, 
according to the WHO guidelines for management of malnutrition. Deaths were notified by parents, 
study staff and community health workers. The families of participants who died at home or at facili-
ties outside the County Hospital were visited by a study nurse to obtain ante-mortem history from the 
primary caregiver using a semi-structured questionnaire.
At each visit, data was entered electronically into a customized Microsoft 2009 SQL® database 
with edit checks and validations. The predetermined sample size was powered to identify incident 
tuberculosis cases, with mortality incidence as a secondary objective.
ethical considerations
The study was approved by the Kenya Medical Research Institute Ethics Committee. (SSC Number 
1465), and conducted according to International Committee for Harmonization of Clinical Trials-
Good Clinical Practice (ICH-GCP). Written Informed consent was obtained from mothers prior to 
initiating study procedures. Study Numbers were assigned to maintain privacy and confidentiality. 
Access to study records was limited to study staff and monitors.
cause of death ascertainment
To obtain the causes of death for post-neonatal mortalities, two medical officers reviewed available 
morbidity data from the study clinic, admission notes and investigations as well as the ante-mortem 
history for deaths that occurred at home. Immediate and underlying causes of deaths were indepen-


































Disagreements were resolved by consensus. Anthropometric data on weight for age was available from 
follow up visits or unscheduled visits. Weight for age Z-Scores from the World Health Organisa-
tion Charts were used to define presence of under-nutrition [18]. Weight of two or more standard 
deviations from the median for age, (≥-2SD) was classified as moderate to severe malnutrition. Weight 
for age Z-scores of greater than one, up to three months before death, were analysed as potential 
underlying risk factor of death.
statistical analysis
To minimize survival bias introduced by variable study entry which could have been related to neo-
natal deaths (left truncation), the analysis time began when infants were six weeks of age and above. 
Follow-up time was censored at 12 months of age. Person-time was calculated from 6 weeks of age 
till 12 months of age, death, or loss to follow-up, whichever occurred first. Descriptive statistics were 
used to describe demographic and clinical characteristics, causes of death and infant mortality rate. 
Unadjusted and adjusted hazard ratios for mortality were computed using Cox proportional hazards 
analysis. Logistic regression was used in bivariate analysis to evaluate the relationship between selected 
predictors. Missing data was excluded.
ResulTs
In 2010, there were 3534 registered births in the study area [19]. The study received 3538 birth 
notifications between June 2009 and June 2010. Of these, 2900 (82%) were enrolled. There were 
46/2900 (1.6%) deaths between birth and six weeks and 326/2900 (11%) were lost to follow (LTFU) 
up at six weeks. Therefore, 2528 infants, six weeks old and above were included in this analysis. Those 
included had together 2020 total person years of follow up. Average person-time was 0.8 person-years. 
At twelve months, cumulative LTFU was 626 (22%).
There were 117 (4.6%) deaths (table 1), between six weeks and twelve months of age. The post- 
neonatal mortality rate was 58 per 1000 person years of follow up (95% CI 48, 69). The post neonatal 
mortality ratio was 46 per 1000 live births. Four in ten deaths occurred at health facilities. Patients 
with sick visits at the study clinic were more likely to be hospitalized (HR 2.55; 95% CI: 1.43, 4.57). 
Immediate causes of death were identifiable in 88/117 (75%) cases. Of these, the most frequently 
identified causes of death were: hypovolemic shock/
dehydration (30%), pneumonia (26%), malaria (10%) 
and anaemia (9%). Together these accounted for 66/88 
(66%) of identifiable deaths (Figure 2a). Of the 36/117 
(31%) cases for which an immediate cause of death could 
not be assigned, 29 cases had inconclusive information, 
and seven had no information at all regarding the ante-
mortem circumstances.
Table 1 | Deaths at the different age groups
age Deaths (n)
0 to 6 weeks 46
>6 weeks to ≤ 4 months 46
>4 months to ≤ 8 months 47 







figure 2a | Immediate Causes of Death n=88/117


































Regarding the underlying causes of death, 110/117 (94%) had information derived from clinical 
notes on co-morbidities which were underlying causes of death. About half of the underlying causes of 
death were attributed to undernutrition 24/110 (22%), diarrheal disease 17/110 (16%) and anaemia 
13/110 (12%). Other frequent underlying causes were infant HIV infection and malaria (Figure 2b).
In the univariate analysis of predictors of mortality, infants born in health facilities had lower hazards 
of mortality, compared to home deliveries (Hazard Ratio (HR) 0.53; 95% CI: 0.35, 0.82). This was 
also observed in the multivariate analysis; adjusted Hazard Ratio (aHR) 0.54; 95% CI: 0.34, 0.84). 
Mothers who had secondary education and above were three times more likely to deliver in a health 
facility. OR 3.02 (95% CI: 2.38, 3.84). A high proportion of HIV positive mothers (16%) transmitted 
the virus to their infants and tens of these infants 26/71 (36%) of the infants tested at six weeks, died 
before HIV results could be disclosed. Infants who were HIV infected were ten times more likely to 
die than uninfected infants; adjusted Hazard Ratio (aHR) 10.3; 95% CI: 6.40, 16.7). HIV uninfected 
infants born to HIV infected mothers were twice as likely to die compared with their counterparts 
born to uninfected mothers; adjusted Hazard Ratio (aHR) 1.72; HR 95% CI: 1.03, 2.90). All these 
effects were consistently observed in the adjusted and unadjusted models (Table 2). Infants whose 
weight for age category was one standard deviation or more from median (WHO growth charts 2009), 
had four times the rates of mortality as peers who had normal weight for age Z score. (HR 4.02; 95% 
CI (1.28, 12.6). However, weight for age Z score was not a statistically significant predictor in the 
adjusted model; adjusted Hazard Ratio (aHR) (2.81; 95% CI: 0.88, 8.96).
Maternal occupation and education and infant gender were not shown to be associated with infant 
survival. However, mothers with secondary education and above were 32% less likely to attend sick 
visits at the clinic OR (0.68 95%CI: 0.50, 0.94), and their infants were 30% less likely to be hospital-
ized OR (0.70 95% CI: 0.55, 0.90). Maternal occupation did not significantly impact the choice of 
home or health facility birth, sick visits nor hospitalisations.
DIscussION
The post-neonatal mortality ratio in the study area was 46 (95% CI: 39, 56) per 1000 live births and 
is comparable to estimates by the Health and Demographic Surveillance System in the general study 
area at the time of the study (52/1000 live births) [20]. Our analysis included infants who survived to 
six weeks of age, rather than to four weeks, hence the lower mortality ratio may be an underestimate. 
The post-neonatal mortality rate (58; 95% CI: 48, 69) per 1000 pyo is higher than a similar study 
in Eastern Uganda, which found 40 per 1000 pyo [21], Eastern Uganda has a less intense malarial 
transmission [19, 22] and antenatal HIV prevalence rates are less than half of those in Western Kenya 
[23].
After controlling for gender, maternal education and occupation, health facility births were sig-
nificantly protective against mortality and infant and maternal HIV infection was associated with 







Unlike previous surveys, we did not find maternal occupation or education to significantly predict 
mortality. Infants of mothers with secondary education attended fewer sick visits and had less frequent 
hospitalisations, therefore, the inability to demonstrate significant mortality benefit could be due to the 
small numbers of these women in the study. We found factors of morbidity such as HIV status, health 
access and utilization (health facility births) to predict mortality at one year of age. This could be due to 
the fact that the study population was relatively homogenous with respect to these socio-demographic 
indices. Alternatively, maternal education and occupation might be intermediate factors of mortality 
that drive health facility use and are less significant in the presence of more direct measures.




















































Total 2528 117 2020 58 N=2440
Gender
Male 1320 66 1037 64 1* 1*
Female 1224 51 983 52 0.82 (0.57, 1.18) 0.87 (0.60, 1.27)
Place of birth
Home 1636 91 1308 70 1* 1*
Health Facility 876 26 699 37 0.53 (0.35, 0.82) 0.54 (0.34,0.84)
Missing 16 0
Mother’s occupation
Not working 1408 67 1110 60 1* 1*
Working 1079 48 878 0.91 (0.63, 1.32) 0.99 (0.68, 1.44)
Unknown 41 2 55
hIV status
Mother HIV negative/Infant HIV negative 2101 75 1681 43 1* 1*
Mother HIV positive/infant HIV negative 316 19 260 73 1.70 (1.02, 2.81) 1.72 (1.03, 2.90)
Infant HIV positive 71 23 46 506 11.1 (6.93, 17.7) 10.3 (6.40, 16.7)
Unknown 40 0
Mother’s education
None/Primary 2174 105 1748 60 1 (ref ) 1*
≥ Secondary 326 10 251 40 0.66 (0.34, 1.25) 0.88 (0.45, 1.69)
Missing 28 2 40
Weight for age at 6 weeks
None to -1SD 2509 114 2007 57 1* 1*
Moderate-Severe (≥-2SD) 19 3 13 230 4.02 (1.28, 12.64) 2.81 (0.88, 8.96)



































Infant HIV infection was negatively associated with survival. A high proportion of HIV positive moth-
ers, (16%), in line with a contemporaneous national survey [24] transmitted the virus to their infants 
and tens of these infants, and (36%) of the 71 HIV infected babies, died before HIV results could be 
disclosed, implying that interventions after transmission has occurred appear to have limited influence 
on mortality. Fortunately, it appears several interventions to reduce Mother To Child Transmission 
(MTCT) are reversing the devastating trend of transmission and HIV mortality [25, 26].
Maternal hIV infection
More recently, these declines in MTCT have turned the focus to HIV exposed uninfected (HEU) 
infants who tested HIV negative but were born to HIV infected mothers who have been shown to have 
higher respiratory and diarrheal disease morbidity, more frequent hospitalisations, impaired immunity 
and growth [27, 28]. Our study tested infants at six weeks, upon suspicion of tuberculosis, and at study 
close out. Mothers were encouraged and supported to initiate ART, and safe feeding practices. We were 
able to show HEUs had higher hazards of mortality at one year, compared to HIV uninfected peers 
born to HIV negative mothers despite these measures. Similar outcomes have been observed in smaller 
studies in Malawi, Uganda [29-31]. Additional effects may be mediated by catastrophic health costs 
incurred in treatment of opportunistic infections which interferes with food security and health care 
access [32]. A sick mother is also unlikely to optimally care for her baby.
Having shown these infants to have increased hazards of mortality, assuring maternal health by 
motivating early initiation into ART and continued compliance could provide the most unified ap-
proach in reducing their vulnerability.
health facility utilization
Health facility deliveries have been known to be protective against perinatal mortality [33, 34]. We 
could not find studies showing medium to long term effects of health facility deliveries. Our study 
showed that one year mortality was significantly lower for infants born in health facilities compared 
to those born at home. Mothers who gave birth in health facilities may have been more likely to use 
facilities in the future for immunization or seeking care for illnesses, leading to a longer term mortality 
benefit.
causes of death
Similar to verbal autopsy reviews of under-five mortality during a similar time period in the same study 
area [35], the majority (60%) of identifiable causes of death were due to severe dehydration follow-
ing gastro-enteritis, pneumonia, malaria and anaemia. There were slight methodological differences 
between that study and ours due to availability of more detailed diagnostic and clinical information to 
our study team. Under-nutrition was identified as underlying cause of death in a third of mortalities. 
Any degree of under-nutrition is known to increase mortality risk [3]. It is frequently underreported as 







potentiating cause of death in up to 53% of deaths in countries in the developing world [36]. In addi-
tion to contributing to excess morbidity, hospitalization and mortality, under-nutrition has irreversible 
long term effects on cognitive development, individual earnings and economic growth [37].
strengths and limitations
Correlates of infant mortality are frequently predicted from surveys and ecological studies [38, 39]. 
Cohort studies are infrequently done. We accessed and followed up a large cohort of infants. Another 
strength is that the study recruited the large majority (82%) of the neonates born at that time in the 
study area. Therefore, we consider the findings largely generalizable to similar settings in Sub-Saharan 
Africa. The study has several limitations. By design, very low and extremely low birth weight infants 
were excluded, possibly under-estimating mortality. We experienced loss to follow up (LTFU) of 21%). 
More than half of this occurred at or before six weeks. This is cultural, closer to delivery pregnant 
women in the study area migrate to be closer to female relatives in proximity and return to their homes 
thereafter. LTFU thereafter was 10%, we therefore consider that this did not significantly impact our 
estimates, as our post-neonatal mortality rate is in line with separate surveys of the study area at the 
same time. Nevertheless it is plausible that exclusion of the early infancy period, we inadvertently 
selected for those with lower risk of mortality. Further, those who were lost to follow up could have 
different health seeking behavior and therefore higher mortality risk. This is unlikely to have shifted 
the results as it was less than 10% for the period under consideration.
cONclusIONs
We have shown that infant HIV infection and exposure significantly increased mortality among in-
fants and that factors of health utilization such as health facility births reduced the hazards of mortality. 
Since then the infant mortality rate in the study area decreased from 52 to 35 deaths per 1000 [40]. 
There is a decline in most of the childhood death indicators in Kenya and the East African Region, 
possibly due to introduction of pneumococcal vaccination in 2011, a leading cause of morbidity and 
mortality in low income countries with high infant mortality [1, 41, 42], as well as scale up of ART 
for infected persons. Our study shows other areas where gains in survival can be improved, such 
as facilitating health facility use and access and scaling up ART among persons living with HIV. 
Ultimately, sustaining and improving on gains in child survival in developing countries will call for 



































 1. Boschi-Pinto C, Bahl R, Martines J. Limited progress in increasing coverage of neonatal and child-health 
interventions in Africa and Asia. J Health Popul Nutr. 2009 Dec;27(6):755-62.
 2. Streatfield PK, Khan WA, Bhuiya A, Hanifi SM, Alam N, Ouattara M, et al. Cause-specific childhood 
mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sites. 
Glob Health Action. 2014;7:25363
 3. Pelletier DL, Frongillo EA, Jr., Schroeder DG, Habicht JP. The effects of malnutrition on child mortality 
in developing countries. Bull World Health Organ. 1995;73(4):443-8.
 4. Wang H, Liddell CA, Coates MM, Mooney MD, Levitz CE, Schumacher AE, et al. Global, regional, and 
national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the 
Global Burden of Disease Study 2013. Lancet. 2014 Sep 13;384(9947):957-79.
 5. Central Bureau of Statistics (CBS) [Kenya]. Kenya Demographic and Health Survey, 2003.
 6. Central Bureau of Statistics (CBS) [Kenya]. Kenya Demographic and Health Survey, 2008.
 7. Central Bureau of Statistics (CBS) [Kenya]. Kenya Demographic Health Survey, 2014.
 8. Schell CO, Reilly M, Rosling H, Peterson S, Ekstrom AM. Socioeconomic determinants of infant 
mortality: a worldwide study of 152 low-, middle-, and high-income countries. Scand J Public Health. 
2007;35(3):288-97.
 9. Kembo J GVJ. Determinants of infant and child mortality in Zimbabwe: Results of multivariate hazard 
analysis. Demographic Research. 2009;21:367-84.
 10. Ettarh RR, Kimani J. Determinants of under-five mortality in rural and urban Kenya. Rural Remote 
Health. 2012;12:1812.
 11. Kanmiki EW, Bawah AA, Agorinya I, Achana FS, Awoonor-Williams JK, Oduro AR, et al. Socio-economic 
and demographic determinants of under-five mortality in rural northern Ghana. BMC Int Health Hum 
Rights. 2014 Aug 21;14:24.
 12. Weldearegawi B, Melaku YA, Abera SF, Ashebir Y, Haile F, Mulugeta A, et al. Infant mortality and causes 
of infant deaths in rural Ethiopia: a population-based cohort of 3684 births. BMC Public Health. 2015 
Aug 11;15:770.
 13. Odhiambo FO, Laserson KF, Sewe M, Hamel MJ, Feikin DR, Adazu K, et al. Profile: the KEMRI/CDC 
Health and Demographic Surveillance System, Western Kenya. Int J Epidemiol. Aug;41(4):977-87.
 14. Phillips-Howard PA, Nahlen BL, Kolczak MS, Hightower AW, ter Kuile FO, Alaii JA, et al. Efficacy of 
permethrin-treated bed nets in the prevention of mortality in young children in an area of high perennial 
malaria transmission in Western Kenya. Am J Trop Med Hyg. 2003 Apr;68(4 Suppl):23-9.
 15. van Eijk AM, Bles HM, Odhiambo F, Ayisi JG, Blokland IE, Rosen DH, et al. Use of antenatal services 
and delivery care among women in rural Western Kenya: a community based survey. Reprod Health. 2006 
Apr 06;3:2.
 16. van Eijk AM, Lindblade KA, Odhiambo F, Peterson E, Sikuku E, Ayisi JG, et al. Reproductive health issues 
in rural Western Kenya. Reprod Health. 2008 Mar 18;5:1.
 17. Central Bureau of Statistics (CBS) [Kenya]. Multiple Indicator Cluster Survey. 2011.
 18. World Health Organisation (WHO). WHO reference growth charts. 2009.
 19. Central Bureau of Statistics (CBS) [Kenya]. The National Population and Housing Census Report. 2009.
 20. Kisumu Heath and Demographic Surveillance System (HDSS) Fact Sheet. 2009.
 21. Nabongo P, Verver S, Nangobi E, Mutunzi R, Wajja A, Mayanja-Kizza H, et al. Two year mortality and 
associated factors in a cohort of children from rural Uganda. BMC Public Health. 2014 Apr 05;14:314.
 22. Pullan RL, Bukirwa H, Staedke SG, Snow RW, Brooker S. Plasmodium infection and its risk factors in 







 23. Byamugisha R, Tylleskar T, Kagawa MN, Onyango S, Karamagi CA, Tumwine JK. Dramatic and sustained 
increase in HIV-testing rates among antenatal attendees in Eastern Uganda after a policy change from 
voluntary counselling and testing to routine counselling and testing for HIV: a retrospective analysis of 
hospital records, 2002-2009. BMC Health Serv Res. 2010 Oct 14;10:290.
 24. Khamadi S, Okoth V, Lihana R, Nabwera J, Hungu J, Okoth F, et al. Rapid identification of infants for 
antiretroviral therapy in a resource poor setting: the Kenya experience. J Trop Pediatr. 2008 Dec;54(6):370-
4.
 25. Nduati EW, Hassan AS, Knight MG, Muema DM, Jahangir MN, Mwaringa SL, et al. Outcomes of 
prevention of mother to child transmission of the human immunodeficiency virus-1 in rural Kenya--a 
cohort study. BMC Public Health. Oct 03;15:1008.
 26. Sarah Finocchario-Kessler KFC, Samoel Khamadi, Brad J. Gautney, Vincent Okoth, Kathy Goggin and 
HITSystem Study Team. Progress Toward Eliminating Mother to Child Transmission of HIV in Kenya: 
Review of Treatment Guideline Uptake and Pediatric Transmission at Four Government Hospitals Between 
2010 and 2012. AIDS behavioral 2016.
 27. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global challenges in the era of 
paediatric HIV elimination. Lancet Infect Dis. 2016;16(6):e92-e107. Epub 2016/03/31.
 28. Weinberg A, Mussi-Pinhata MM, Yu Q, Cohen RA, Almeida VC, Amaral FR, et al. Factors Associated 
with Lower Respiratory Tract Infections in HIV-Exposed Uninfected Infants. AIDS Res Hum Retroviruses. 
2018;34(6):527-35. Epub 2018/04/23.
 29. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed 
uninfected children: a growing population with a vulnerable immune system? Clin Exp Immunol. 2014 
Apr;176(1):11-22.
 30. Landes M, van Lettow M, Chan AK, Mayuni I, Schouten EJ, Bedell RA. Mortality and health outcomes 
of HIV-exposed and unexposed children in a PMTCT cohort in Malawi. PLoS One. 2012;7(10):e47337.
 31. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, Nalugoda F, et al. Mortality in 
HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir 
Immune Defic Syndr. 2006 Apr 1;41(4):504-8.
 32. Barennes H, Frichittavong A, Gripenberg M, Koffi P. Evidence of High Out of Pocket Spending for HIV 
Care Leading to Catastrophic Expenditure for Affected Patients in Lao People’s Democratic Republic. 
PLoS One. 2015;10(9):e0136664.
 33. De Brouwere V, Tonglet R, Van Lerberghe W. Strategies for reducing maternal mortality in developing 
countries: what can we learn from the history of the industrialized West? Trop Med Int Health. 1998 
Oct;3(10):771-82.
 34. World Health Organisation (WHO). World Health Organization fact sheet. Making pregnancy safer. 
Saudi Med J. 2004 Aug;25(8):1133-5.
 35. Amek NO, Odhiambo FO, Khagayi S, Moige H, Orwa G, Hamel MJ, et al. Childhood cause-specific 
mortality in rural Western Kenya: application of the InterVA-4 model. Glob Health Action. 2014;7:25581.
 36. Pelletier DL, Frongillo EA, Jr., Habicht JP. Epidemiologic evidence for a potentiating effect of malnutrition 
on child mortality. Am J Public Health. 1993 Aug;83(8):1130-3.
 37. Bezanson K, Isenman P. Scaling up nutrition: a framework for action. Food Nutr Bull. 2010 Mar;31(1):178-
86.
 38. Izugbara C. Single motherhood and neonatal and infant mortality in Sierra Leone, Burkina Faso and 
Burundi. Public Health. 2016 Jun;135:122-30.
 39. Hammer GP, Some F, Muller O, Kynast-Wolf G, Kouyate B, Becher H. Pattern of cause-specific childhood 


































 40. Sifuna P, Otieno L, Ogwang S, Ogutu B, Andagalu B, Owuoth J, et al. Cause-specific mortality in the 
Kombewa health and demographic surveillance systems site, rural Western Kenya from 2011-2015. Glob 
Health Action. 2018;11(1):1442959.
 41. Ayieko P, Griffiths UK, Ndiritu M, Moisi J, Mugoya IK, Kamau T, et al. Assessment of health benefits 
and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. 
PLoS One.8(6):e67324.
 42. Rurangwa J, Rujeni N. Decline in Child Hospitalization and Mortality After the Introduction of the 
7-Valent Pneumococcal Conjugative Vaccine in Rwanda. Am J Trop Med Hyg. 2016 Sep 07;95(3):680-2.




Chest radiographs for paediatric TB 
diagnosis: Inter-rater agreement and utility
Grace Kaguthi, Videlis Nduba, Jocelyn Nyokabi
Franklin Onchiri, Robert Gie, Martien W. Borgdorff








Introduction: The chest radiograph (CXR) is considered a key diagnostic tool for paediatric Tubercu-
losis (TB) in clinical management and endpoint determination in TB vaccine trials.
Methods: We set out to compare inter-rater agreement for TB diagnosis in western Kenya. A paediat-
ric pulmonologist and radiologist (experts), a medical officer (M.O) and four clinical officers (C.Os) 
with basic training in paediatric CXR reading, blindly assessed CXRs of infants who were TB suspects 
in a cohort study. C.Os had access to clinical findings for patient management. Weighted kappa 
scores summarized inter-rater agreement on lymphadenopathy and abnormalities consistent with TB. 
Sensitivity and specificity of raters was determined using microbiologically confirmed TB as the gold 
standard (n=8).
Results: A total of 691 radiographs were reviewed. Agreement on abnormalities consistent with TB 
was poor; k=0.14; (95%CI: 0.10 - 0.18), and on lymphadenopathy moderate k=0.26 (95%CI: 0.18 
- 0.36), M.O [75% (95 %CI: 34.9%-96.8%)] and C.Os [63% (95%CI: 24.5%-91.5%)] had high 
sensitivity for culture confirmed TB.
conclusion: TB vaccine trials utilizing expert agreement on CXR as a non-microbiologically con-
firmed endpoint will have reduced specificity and underestimate vaccine efficacy. C.Os detected many 
of the bacteriologically confirmed cases, however this must be interpreted cautiously as they were 








































Paediatric TB remains a challenging disease to diagnose despite advances in molecular techniques in 
mycobacterial identification and antigen based tests for latent TB infection(1). Classical TB symptoms 
are nonspecific [2] and more so in settings with high HIV prevalence and malnutrition. Atypical 
presentation with acute severe pneumonia in young children has been observed [3]. Childhood TB 
is characterized by paucibacillary disease and microbiological confirmation is only possible in <50% 
of paediatric cases [1]. Chest imaging is therefore of great importance in identifying smear negative, 
culture negative TB. Among adults with suspected TB, several clearly defined chest radiograph features 
have been identified as having high inter rater reliability and correlation with culture positive TB [4] 
Unfortunately similar data among infants has been limited. Lymphadenopathy is the hallmark of 
primary TB [5]. However, it is frequently missed due to inadequate sensitivity of the chest radiograph 
[6]. Chest CT Scan (CT) has been considered the gold standard for detecting mediastinal lymphade-
nopathy, detecting up to 60% more lymphadenopathy in children with normal chest radiographs [7]. 
Despite this, use of CT has been limited in infant TB vaccine trials, which are set up to detect every TB 
endpoint so as to demonstrate efficacy. Reasons include; the modest agreement on lymphadenopathy on 
CT [7], cost limitations and the reluctance to use high dose ionizing radiation in young children. Thus, 
the chest radiograph is the mainstay of radiological diagnosis, and is frequently the only tool available.
There are a limited number of studies that have described inter rater agreement on chest radiograph 
for TB diagnosis [8, 9]. Existing studies had small sample sizes, were drawn from hospitalized children, 
compared agreement only among experienced and highly trained raters, and most importantly, they 
focused entirely on presence of lymphadenopathy as a marker of TB. While lymphadenopathy is a key 
feature to diagnosing childhood TB, other radiological features also contribute to the diagnosis [5, 6]
We conducted the study in Siaya County, Western Kenya, which has a high burden of both tuber-
culosis and HIV [10, 11]. The objective was to determine inter rater agreement on any abnormality 
on chest radiograph, and agreement on abnormalities consistent with TB among experienced and 
inexperienced raters. We also aimed to compare the raters’ sensitivity and specificity against microbio-
logically confirmed TB in young children.
sTuDy POPulaTION aND MeThODs
study setting
The study was conducted in Siaya County, Western Kenya from June 2009 to December 2011. TB 
diagnosis is by the Keith Edward Score Chart [12] which assigns a score to suggestive pulmonary and 
extra-pulmonary signs/symptoms of TB. Children who score ≥7 as well as those who score <7 but have 
an abnormal chest radiograph are treated for TB. A total of 2900 BCG vaccinated infants, aged zero to 
six weeks and weighing at least 1700g were enrolled and followed up for 12-24 months to determine 







by review of TB case records for contact tracing. Suspect criteria included, a history of contact and/or 
suggestive signs and symptoms of TB, and/or protocol defined hospitalization history for example for 
severe pneumonia.
clinical and laboratory Investigations
TB suspects were admitted into a case verification ward (CVW) for collection of two serial induced 
sputa specimens, two serial early morning gastric aspirates, DNA PCR HIV (HIV QUAL test 48 Roche 
Molecular Systems Inc, Switzerland ) testing and Rapid HIV tests for those aged less than and greater 
than 18 months respectively. Tuberculin Skin Testing was also done. Digital antero-posterior (AP) and 
lateral chest radiographs were taken at admission and images written into CD-ROMs. The CD-ROMs 
had Digital Imaging and Communication in Medicine (DICOM) software (Phillips) that was used to 
view images. Readers could optimize the light/greyscale settings, as well as the magnification.
Definitions and classifications
Microbiologically confirmed TB (Definite TB) was M. tuberculosis identified by Xpert MTB/RIF 
or speciated with either Capilia (FIND and Tauns co. Ltd) or GenoType assay (Hain Diagnostika, 
Nehren, Germany) after positive sputum culture. Probable TB was a case started on anti-TB treatment 
based on Keith Edward Score Chart and/or a CXR consistent with TB.
Raters and Training
There were four sets of raters: A Radiologist and a Paediatric Pulmonologist (expert readers), a Medical 
Officer (M.O) and four Clinical Officers (C.Os). The C.Os reviewed the images while the suspects were 
admitted to the CVW, all other raters read the images after close of the study and were blinded to the 
clinical history. All raters were trained on using the electronic interface to enter readings. The Clinical 
and Medical Officer(s) were trained on reading and identifying TB on paediatric radiographs prior to 
the start of the study. A chest radiograph reading form developed during a consensus meeting of TB 
vaccine sites (Cape Town December 2008) was used. An electronic version was developed to standardize 
reporting and minimize ambivalence in the diagnosis. The technical quality of images was assessed prior 
to reading. Indicators included: adequacy of collimation (visibility of the lung apices, costophrenic angles 
with nothing obscuring the lung fields), adequate exposure; the number of visible intervertebral spaces; 
adequate inspiration, by counting six anterior ribs, absence of rotation by comparing the length of the 
same rib on the left and right hemidiaphragms. Thereafter, the reader classified the chest radiograph 
quality as optimal or suboptimal or unreadable. ‘Unreadable’ radiographs were counted as suboptimal 
but were still read. Raters then systematically reviewed the images for airway narrowing, left tracheal 
deviation, lymphadenopathy, airway opacities, calcification and pleural effusion. The pathology items 
were scored individually as present, absent, and equivocal. Final assessment of the image was; normal ra-
diograph; abnormal TB unlikely; abnormal TB likely. Radiological signs suggestive of TB were: miliary 
picture, airway narrowing or tracheal deviation to the left, presence of hilar, paratracheal or subcarinal or 







































Data collection and analysis
Data quality was assured by edit, logic and validation checks built onto the data entry interface. Data 
cleaning was also conducted, and an audit trail of changes maintained. Data was saved onto an SQL 
database and analysed using SAS 9.0 (SAS Institute Inc, Cary NC, USA). To quantify degree of agree-
ment in TB diagnosis among the raters, we estimated the individual kappas for each rating category 
as well as a generalized (multiple rater) chance-corrected kappa statistic (a multi-rater measure of 
agreement), which is an extension of Cohen’s kappa for assessing reliability or proportion of agreement 
for multiple raters. The overall/generalized kappa measures agreement across all categories.
Kappa scores were interpreted as follows: Poor 0.01-0.20, moderate 0.21-0.40, fair 0.41-0.60, good 
0.61-0.80 or excellent 0.81-1.0 (13). We compared agreement on any abnormality on chest radio-
graph, as well as agreement on abnormalities consistent with TB. For comparability with previously 
conducted paediatric chest radiographs studies we examined the agreement on lymphadenopathy on 
AP and lateral images. Sensitivity and specificity of readers’ diagnosis to definite TB was also calcu-
lated. To examine each rater’s propensity to place a radiograph in a certain category, and thus elucidate 
patterns of agreement, McNemar Test for 2X2 tables, and Bowker’s Test of symmetry were applied for 
tables with more than two categories. These methods compare marginal frequencies of each rater and 
test for statistically significant differences (Tests of marginal homogeneity). Where p<0.05, marginal 
heterogeneity exists that is, differing propensity to rate a category.
The study was reviewed and approved by the Kenya Medical Research Institute Ethics Review 
Committee, (KEMRI-ERC) SSC 1465. Written Informed consent was obtained from parents and 
Guardians before study entry and for CVW investigations.
ResulTs
TB suspects comprised 33% of those enrolled (959/2900). Of these, 767 (80%) consented to CVW 
admission for additional investigations and 837 chest radiographs were taken (Figure 1).
There were similar numbers of male (51.5%) and female (49.5%) suspects. Some of the prevalent 
co-morbid conditions among suspects included HIV exposure- nearly one-fifth (17.3%), HIV infec-
tion (4.4%) and malnutrition (46.0%). Close to half of investigated infants 355/767 (46.3%) had 
been hospitalized with severe lower respiratory tract infections such as bronchiolitis and pneumonia. 
Prevalence of acute and chronic malnutrition was as follows; wasting (WHZ < -2) n=167/767 (21.7% 
) stunting (HAZ <-2) 82/767 (10.2%) and underweight (WAZ <-2)104/767 (13.6%).
Agreement on CXR reading was low overall. For abnormalities consistent with TB (Table 1a and 
1b), poor to moderate agreement was observed across all rater pairs: pulmonologist-radiologist (k=0.24 
(95% CI: 0.15-0.34)); pulmonologist-medical officer (k=0.21(95% CI: 0.13-0.29)) and radiologist-







On any abnormality on the radiograph, agreement was moderate between expert readers [k=0.28 
(95% CI: 0.19-0.37)] and between expert readers and M.O. [Pulmonologist vs medical offi  cer (k=0.23 
(95% CI: 0.15-0.31)] and [Radiologist vs Medical Offi  cer (k= 0.22 (95% CI: 0.14-0.30)] respectively. 
(Table 3). Poor- agreement was registered across all other rater pairs. Th ere was similar propensity to 
rate categories between the expert pair (p=0.14) and between the radiologist and the clinical offi  cer 
(p=0.24). Regarding quality of radiographs, little or no agreement was registered across all rater pairs. 
Th e best kappa score was 0.07 (0.03-0.10), observed between the expert pair. (Table 4). Th ere were 
eight defi nite and 40 probable TB cases in the study. One radiograph of a defi nite TB case was not 
reviewed by all four raters. Th e sensitivity and specifi city of raters (Table 5) was determined using 
defi nite TB cases as the gold standard (n=8).
figure 1 | Profi le of presumptive TB cases and chest radiographs read per rater
* per patient more than one CXR could have been taken
Table 1a | Inter-rater agreement on abnormalities consistent with TB
Outcome Kappa (95% cI) P value
TB Classifi cation Category
Abnormal 0.177 (0.124 - 0.237) <0.001
Abnormal likely TB 0.193 (0.095 – 0.330) <0.001
Abnormal unlikely TB 0.065 (0.026 – 0.125) <0.001







































Table 1b | Inter-rater agreement on abnormalities consistent with TB
RADIOLOGIST
Total
















































































Normal 345 5 30 12 0 3 18 0 4 417
Abnormal
likely TB
5 1 3 1 0 1 0 0 2 13
Abnormal
unlikely TB
83 1 20 3 1 5 10 1 6 130
Abnormal
likely TB
Normal 12 1 1 0 0 1 0 0 0 15
Abnormal
likely TB
1 0 0 1 3 0 0 1 0 6
Abnormal
unlikely TB




Normal 51 1 4 3 0 2 4 2 1 68
Abnormal
likely TB
4 1 0 1 1 2 0 0 0 9
Abnormal
unlikely TB
10 0 2 2 1 1 4 2 1 23
Total 515 11 60 24 7 16 38 6 14 691
Agreement among all raters on the diagnosis of lymphadenopathy was moderate, with a multi-rater weighted 
k=0.26 (Table 2).
Table 2 | Overall agreement amongst all raters on lymphadenopathy and quality of CXR
Rating Kappa (95% cI) P value
Lymphadenopathy
Present 0.27 (0.129–0.448) <0.001
Absent 0.29 (0.163–0.430) <0.001
Equivocal 0.17 (0.044–0.423) <0.001












Table 3 | Agreement on any abnormality on chest radiograph (+) abnormal/ (-) normal
N = 691
Reader -/- -/+ +/+ +/- Kappa McNemar’s Test
radiologist vs 
pulmonologist
515 62 43 71 0.28 (0.19-0.37) 0.44
pulmonologist vs M.O 445 132 59 55 0.23 (0.15-0.31) <0.0001
radiologist vs M.O 450 136 55 50 0.22 (0.14-0.30) <0.0001
pulmonologist vs cO 477 100 31 83 0.10 (0.01-0.18) 0.21
radiologist vs c.O 493 93 38 67 0.18 (0.10-0.27) 0.04
c.O vs M.O 417 143 48 83 0.10 (0.02-0.17) <0.0001














radiologist vs pulmonologist 29 295 301 7 0.07 (0.03-0.10) <0.0001
pulmonologist vs M.O 10 37 271 314 -0.09 (-0.13- -0.05) <0.0001
radiologist vs M.O 2 45 551 34 -0.02 (-0.09- 0.05) 0.22
pulmonologist vs cO 7 5 303 317 0.005 (-0.02-0.03) <0.0001
radiologist vs c.O 2 12 586 34 0.06 (-0.05-0.16) 0.0003
c.O vs M.O 0 12 573 47 -0.03 (-0.05- -0.02) <0.0001























































































The clinical and medical officer(s) detected the largest proportion of definite TB, while specificity 
was highest for expert raters. Due to the small number of definite cases, sensitivity was imprecisely 
measured. The same table shows low positive predictive values (PPV) (<4.0% for all raters) and high 
negative predictive values (>99.0% for all raters) for the chest radiograph of 28/40 (70%) probable TB 
cases whose chest radiographs were read by all raters, experts agreed on only two as being consistent 
with TB. Such would be the stringent case definition applied in infant TB vaccine trials [14] where 
only radiographs in which experts agreed (Figure 2) would be admissible as non-microbiologically 
confirmed TB cases.
DIscussION
Overall, we observed poor to moderate agreement between experts and between expert, non-expert 
pairs. This was consistent across the rater’s summary opinion of radiograph:-as well as on specific 
pathology such as lymphadenopathy. Our findings fit in with other studies comparing inter-rater 
agreement on lymphadenopathy for TB diagnosis [9]. Additionally, we demonstrate that agreement is 
also poor for the composite assessment of the radiograph, beyond individual radiographic abnormali-
ties. This undermines the reliability of the chest radiograph for TB diagnosis in infant vaccine trials, as 
well as possibly for clinical diagnosis and patient care. We suggest several contributing factors. In an 
infant cohort study with active case finding, suspects are likely to be picked up and investigated before 
advanced disease with well-defined radiographic features sets in. Early tuberculosis is likely associated 
with greater diagnostic uncertainty and risk of misclassification [15]. Inter rater agreement studies in a 
clinical setting where TB suspects may present with more advanced disease are needed to confirm this.
A study of two large infant cohorts in South Africa showed frequent discordance between radiologi-
cal and microbiological features of TB [2, 16]. The absence of clear, defined radiological abnormalities 








that correlate well with microbiologically confirmed disease contributes to lack of a reproducible, 
standardized criteria that raters can use with certainty to evaluate radiographs.
In radiographs of young children, mediastinal abnormalities are difficult to assess and interpret 
[17] particularly in inexperienced readers; in this case the C.O and M.O. However, even experienced 
readers have been found to have poor agreement on lymphadenopathy on chest radiographs [9].
Previous studies had smaller sample sizes for assessment of inter rater variability[8, 9] One of the 
strengths of this study is the inclusion of a large sample of radiographs for evaluation, from young chil-
dren with a broad range of respiratory illness and co morbidities. The varying levels of raters’ expertise 
represents the general clinical care structure from primary level to specialized referral hospitals. The 
findings are therefore applicable to a broad range of settings.
The study had limitations. It was not possible to obtain consensus from expert readers on radio-
graphs on which they differed. This would have increased agreement scores and validity of the chest 
radiograph as a diagnostic tool. It would also have elucidated patterns of disagreement, in order to 
refine criteria for identifying pathologies consistent with TB on chest radiographs as has been previ-
ously recommended [9]. Obtaining high inter rater agreement for paediatric chest radiographs in 
acute paediatric respiratory illness is difficult. Pneumococcal vaccine trials have succeeded in this for 
opacities consistent with pneumonia on paediatric chest radiographs[18] Unfortunately, it has been 
difficult to replicate this success in TB vaccine trials.
Conventionally, TB vaccine trial efficacy sample sizes are calculated based on composite endpoints. 
These include bacteriological and non-bacteriological criteria as it is expected microbiologically con-
firmed cases will contribute a limited number of endpoints. To increase the number of endpoints, and 
thus reduce sample size requirements, non-bacteriologically confirmed endpoints that rely on chest 
radiograph findings are included. The latter is defined as radiographic findings compatible with tuber-
culosis identified independently by two experts [15, 19]. This approach has some limitations. We found 
that experts agreed only on five of 35 radiographs, as being consistent with TB. Of these, three were 
bacteriologically confirmed, therefore the chest radiograph contributed only two additional endpoints. 
Poor agreement and high variability in interpreting paediatric CXRs for TB diagnosis among experts 
increases the probability of misclassifying true disease status and thus underestimating vaccine efficacy 
[20]. C.Os and M.Os, picked up majority of the cases, that were later bacteriologically confirmed. 
This would seem like a positive outcome, given that they work as primary health care providers and 
would therefore accelerate diagnosis and treatment of infants with TB. However, the limited number 
of definite cases results in imprecise estimates of sensitivity and should be cautiously interpreted. The 
high sensitivity also trades off on specificity and could result in unnecessary TB treatment.
Prevailing disease rates influence predictive values. Among infants, the TB incidence of 1.12% (95% 
CI 0.54%-2.36%) would be considered high, however low PPV relative to sensitivity is attributed 
to low disease rates. While the NPV was high, where prevalence is not much above 1%, even a non-








































Poor agreement and high variability in classifying paediatric radiographs underscores need for caution 
in diagnosing TB in clinical settings where bacteriological confirmation is unavailable; as in most 
resource limited settings. It further demonstrates that addition of radiographic, non-bacteriologically 
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Introduction: There is inadequate understanding of the epidemiology of Non Tuberculous Mycobac-
teria (NTMs) among infants in high tuberculosis burden countries. The objective of this study was 
to document the incidence and diversity of NTM disease or colonisation in sputum specimens from 
infants with presumptive TB, the risk factors and clinical characteristics, in a high TB & HIV burden 
setting in Western Kenya.
Methods: A cohort of 2900 newborns was followed for 1–2 years to assess TB incidence. TB investiga-
tions included collection of induced sputa and gastric aspirates for culture and speciation by HAIN, 
Tuberculin Skin Testing (TST), HIV testing and chest radiography. The American Thoracic Society 
Criteria (ATS) were applied to identify NTM disease.
Results: Among 927 (32% of 2900) with presumptive TB, 742 (80%) were investigated. NTMs 
were isolated from 19/742 (2.6%) infants. M. fortuitum was most frequently speciated (32%). Total 
person-time was 3330 years. NTM incidence was 5.7/1,000 person-years; 95% CI (3.5, 8.7). Infants 
diagnosed with TB were more likely to have NTM isolation (odds ratio 11.5; 95% CI 3.25, 41.0). 
None of the infants with NTM isolated met the criteria for NTM disease.
conclusion: The incidence of NTM isolation was comparable to similar studies in Africa. NTM 
isolation did not meet ATS criteria for disease, and could represent colonisation. TB disease appears to 


































Non Tuberculous Mycobacteria (NTMs) are environmental saprophytes widely distributed in water 
and soil (1). They are the genetic progenitors of M. tuberculosis Complex (MTBC), after a series of 
gene deletions and gene acquisitions (2) with MTBC evolving to a more virulent pathogen. NTMs 
rarely cause disease except when immune function is impaired (3), elderly patients and chronic lung 
disease. However, some NTMs are pathogenic, and recently there has been a reported increase in 
NTM lymphadenitis (4, 5) and Buruli ulcers (6, 7).
The shared ancestry of NTM and MTBC is responsible for immune interference in BCG vaccina-
tion, via cross reactive immune responses (2). This could be one of the reasons for low BCG efficacy 
where NTMs are prevalent (2). Absence of NTM sensitization was associated with higher efficacy 
of BCG against pulmonary and severe forms of tuberculosis in a systematic review (8). Surprisingly, 
the discontinuation of universal BCG vaccination in these countries has seen an increase of NTM 
lymphadenitis in children, suggesting BCG was also protecting against NTMs in that setting (4). 
NTMs appear to be immune modulators influencing host interactions in BCG efficacy, TB burden 
and NTM disease. The antigen homologues (2) further decrease accuracy of biomarkers distinguishing 
latent TB infection (LTBI) and NTM exposure.
Pulmonary NTM disease is clinically and radiologically identical to TB, and is so diagnosed, in the 
absence of microbiological confirmation in high TB burden settings. It is a relevant distinction to make 
as almost all NTMs do not respond to anti-tuberculous therapy (9). Isolation of NTM in sputum is not 
necessarily disease (9). Data on NTM disease and prevalent subtypes is limited particularly in countries 
with a high TB burden.. Most studies report on adults (10-12). Few studies on NTM in children have 
been published on the continent (13-15). Most document the proportion of NTM among those with 
presumptive TB. There is also a dearth of knowledge on risk and exposure factors. As infants are the 
target age group for TB vaccines in the pipeline, it is useful to describe the epidemiological landscape 
of NTMs, given their role in tuberculosis incidence and possibly vaccine efficacy.
The objective of this study was to document the incidence and diversity of NTM disease or 
colonisation in sputum specimens from infants with presumptive TB, the risk factors and clinical 
characteristics, in a high TB & HIV burden setting.
study population and methods
The study took place in Siaya, Western Kenya, a predominantly rural community north of Lake 
Victoria. The area has a high prevalence of HIV, TB and malaria. Most women delivered at home (16). 
The NTM sub-study was part of a prospective cohort study to document the incidence of TB ahead 
of TB vaccine trials in the same population. Presumably, infants are born uninfected we present the 
incidence of NTM in this cohort.
Briefly, parents or guardians of 2900 infants aged zero to six weeks gave written permission for 
enrolment of their newborns between June 2009 and June 2010. Patients were followed up for at least 







infants were identified as having presumptive TB if they had history of TB contact, symptoms or signs 
of pulmonary TB (failure to thrive, cough or night sweats or fever for more than two weeks, a history 
of hospitalization for HIV/AIDS related illness, lower respiratory tract infections, meningitis or TB). 
Consequently, they were admitted into a case verification ward for three days. Two fasted sputum 
induction specimens and two gastric aspirates were collected on subsequent mornings. Tuberculin Skin 
Testing (TST) was done with two Tuberculin Units (2TU) from Statens Serum Institute (SSI). TST 
readings of 10mm and more, or 5mm or more among HIV infected children were considered to be 
positive readings. Further, DNA PCR HIV (COBAS® HIV-1 Amplicor by ROCHE) tests and digital 
chest radiography were performed.
Patients received anti-tuberculous therapy if they had microbiological confirmation (definite TB) or 
clinically, based on the Keith Edward TB Score (KE Score) Chart of >7, or <7 if the chest radiograph 
was suggestive (probable TB). Mid upper Arm Circumference (MUAC) was used to determine nutri-
tional status for children older than 6 months old at time of TB investigations. Weight for Age Z Score 
was used for those less than 6 months. HIV infected infants were referred for anti-retroviral treatment 
initiation and care. Patients vital status at last study contact was documented.
Chest radiographs were read systematically and classified as Abnormal probable TB, Abnormal not 
TB or Normal (17). The study was approved by Kenya Medical Research Institute Independent Ethics 
Committee (KEMRI-IEC) SSC 1465. The data used to support the findings of this study are available 
from the corresponding author upon request. We applied the American Thoracic Society’s (18) criteria 
to establish clinical significance of positive NTM cultures.
laboratory Methods & sample Decontamination
Induced sputum and gastric aspirates were transported to the laboratory at 2 - 80C, processed using 
freshly prepared N-acetyl L-cysteine (NALC)-4% Sodium Hydroxide (NaOH)-2.9% Sodium citrate 
at a final concentration of 1%. Gastric aspirates with >5ml volume, were concentrated by centrifuga-
tion and pellet re-suspended with 5ml phosphate buffer saline (PBS). Digestion was stopped using pH 
6.8 PBS after 20 minutes. Centrifugation was done at 3,000 x g for 15 minutes at 40C. Supernatant 
was discarded and the pellet re-suspended with 2ml PBS. This was used for inoculation of Lowenstein 
Jensen (LJ) [BD] media (0,2ml), fluorescent microscopy and mycobacteria growth indicator tube 
(MGIT) [BD] (0.5ml). LJ were incubated in 370C CO2 incubators for 8 weeks, MGIT was incubated 
in automated BACTEC TM MGIT TM 960 [BD] for 42 days. Artificial sputum was used as a negative 
control sample to check for cross-contamination with each batch processed.
MGIT cultures that turned positive were stained for acid fast bacilli (AFB) using Ziehl Neelsen 
(ZN). Contamination was checked by inoculation and incubation of blood agar plates at 370C and 
read after 48 hours. Samples that tested ZN negative but Blood Agar Plate (BAP) positive ≥7 days 
later were discarded as contaminated. Those <7 days were re-digested using 4% NaOH as described 
in MGITTM procedure manual (19). AFB positive cultures were tested by immunochromatographic 
assay (ICA) such as CapiliaTM TB-Neo (TAUNS Laboratories, Numazu, Japan) or BD MGITTM 

































LJ cultures with visible growth, we assessed colony morphology. Th ose suggestive of mycobacteria 
were identifi ed using ZN smear, those AFB positive were tested with ICA. NTM culture isolates were 
genetically identifi ed to the species level using Genotype Mycobacterium Common Mycobacterium 
(CM) or Additional Species (AS) kits (HAIN Lifescience, Nehren, Germany). Th e procedure was done 
according to manufacturer’s instructions.
statistical Methods
Frequency methods were used to describe the baseline characteristics. Odds ratios were used to analyze 
whether diff erences between those with and without NTM were due to chance. T-tests was used to 
compare the mean age at TB investigations. To evaluate diff erences in clinical characteristics, known 
and potential risk factors, logistic regression was performed. NTM cases that had microbiologically 
confi rmed or clinical TB were analysed as TB cases. A-priori risk factors included infant and maternal 
HIV infection, nutritional status, housing and number of siblings.
ResulTs
Of 2900 infants enrolled, 927 (32%) were suspected to have TB (presumptive TB) during their 1-2 
year follow-up. Of these 742 (80%) were admitted for investigations (Figure 1).
Th ere were 19 NTMs identifi ed following culture (2.6% of 742). Total person-time of follow-up 
was 3330.3 years. Th e incidence of NTM was 5.7 per 1,000 person years (pyo) of follow up (95% CI 
3.5, 8.7), while all TB incidence (49 cases) was 15/1000 pyo (95% CI:11-20) and microbiologically 
confi rmed TB incidence was 2.7/1,000 pyo. At baseline there were no statistically signifi cant diff er-
ences between those who had NTMs identifi ed versus all other infants (Table 1).











(N = 742) (N, column %)
NTM positive
(N = 19) (N, row %)
OR (95%CI) **
Gender
female 1412 358 (48%) 10 (2.8%) 1*
male 1488 384 (52%) 9 (2.3%) 0.85 (0.35, 2.11)
enrolment weight
normal 2674 667 (90%) 16 (2.4%) 1*
low 226 75 (10%) 3 (4.1%) 2.24 (0.65, 7.73)
Place of birth
health facility 1038 229 (31%) 8 (3.5%) 1*
home 1840 510 (69%) 11 (2.2%) 0.77 (0.31, 1.93)
missing 22 3 (<1%)
Maternal hIV status
negative 2451 598 (81%) 16 (2.7%) 1*
positive 401 127 (17%) 3 (2.4%) 0.88 (0.25, 3.08)
unknown 48 17 ( 2%)
Infant hIV status
negative 2827 708 (95%) 18 (2.5%) 1*
positive 73 34 (5%) 1 (2.9%) 2.17 (0.29, 16.5)
Maternal age category
<19 635 152 (21%) 1 (0.7%) 1*
20 – 29 1533 384 (52%) 16 (4.2%) 6.69 (0.89, 50.5)
>29 732 206 (28%) 2 (1.0%) 1.74 (0.16, 19.2)
Maternal Occupation
unemployed 1676 409 (55%) 11 (2.7%) 1*
farmer 864 250 (34%) 5 (2.0%) 0.88 (0.31, 2.54)
business 260 61 (8%) 2 (3.3%) 1.17 (0.26, 5.32)
salaried 71 13 (2%) 1 (7.7%) 2.16 (0.28, 17.0)
unknown 29 9 (1%)
housing type
mud house 1912 523 (71%) 11 (2.1%) 1*
semi-permanent 527 125 (17%) 4 (3.2%) 1.32 (0.42, 4.17)
permanent 426 84 (11%) 4 (4.8%) 1.64 (0.52, 5.17)
other 6 1 (0.1%)
unknown 29 9 (1.2%)
Number of siblings
none 649 129 (17%) 3 (2.3%) 1*
one to three 1497 391 (53%) 14 (3.6%) 2.03 (0.58, 7.10)
>3 754 222 (30%) 2 (0.9%) 0.57 (0.10, 3.44)
Vaccination status at 6 weeks
incomplete 133 29 (4%) 2(7.0%) 1*
complete 2205 682 (92%) 16(2.4%) 0.48 (0.11, 2.10)
unknown 562 31 (4%) 1(3.2%)
* 1 = set as the reference

































Upon bivariate comparison of clinical characteristics between presumptive TB patients and NTM 
cases, there were no statistically significant differences (Table 2a).
However, odds of a positive NTM among infants with TB was eleven fold that of infants with no TB 
(OR 11.6 (95% CI 3.25, 41.0). NTM cases had forty eight fold higher odds of having microbiologi-
cally confirmed TB compared to all presumptive TB (OR 48.3 95% CI 9.3, 249) (Table 2a). There 
were no differences between NTM cases and other presumptive TB cases in mean age at time of TB 
investigations (Table 2b).
Table 2a | Clinical characteristics of infants investigated for TB and with NTM isolated
clinical characteristics Investigated for Tb
(N = 742) (N, column %)
NTM positive
(N = 19) (N, row %)
OR (95%CI) **
Tb case (clinical / confirmed)
no 694 (94%) 16 (2.3%) 1*
yes 48 (6.5%) 3 (6.3%) 11.6 (3.25, 41.0)
MTb culture positive
no 733 (99%) 17 (2.3%) 1*
yes 9 (1%) 2 (22.2%) 48.3 (9.34, 249)
chest radiograph
normal 590 (80%) 13 (2.2%) 1*
abnormal – not TB 110 (15%) 4 (3.6%) 1.71 (0.55, 5.35)
TB 35 (5.0%) 2 (5.7%) 2.80 (0.61, 12.9)
missing 7 (0.9%)
Keith edward Tb score
< 7 675 (90%) 17 (2.5%) 1*
≥ 7 32 (4.3%) 2 (6.3%) 2.62 (0.58, 11.9)
Missing 35 (4.7%)
history of hospitalization
no 283 (38%) 8 (3.4%) 1*
yes 426 (57%) 11 (2.6%) 0.78 (0.31, 1.97)
missing 33 (5.0%) 8 (3.4%)
Tb contact history
no 579 (78%) 13 (2.3%) 1*
yes 131 (18%) 6 (4.6%) 2.57 (0.96, 6.88)
missing 32 (4.0%) 13 (2.3%)
TsT result
negative 555 (76%) 14 (74%) 1*
positive 172 (24%) 5 (26%) 1.15 (0.41, 3.25)
* 1 = set as the reference







Table 3 shows the NTMs identified and the individual’s clinical characteristics. M. fortuitum (6/19 
32%) and (M. scrofulaceum 2/19 11%) were most frequently isolated.
Two of the 19 (11%) were unidentifiable. Two patients had MTB and NTM co-infection. Applying 
the ATS criteria for diagnosis of NTM disease, none of the NTM cases qualified as having NTM 
disease. Only 1/19 (5.3%) NTM case was HIV infected (Table 3b) while 3/19 (16%) were born to 
mothers who tested HIV positive but were themselves uninfected (HUE).
In our study, rapidly growing mycobacteria (RGM) which form colonies in less than seven days, 
were isolated most frequently (10/19) (Table 3a). The most frequently isolated NTM in paediatric 
studies are shown in Table 4. M. fortuitum was the most frequently isolated NTM among the identified 
studies.
Table 2a | Clinical characteristics of infants investigated for TB and with NTM isolated
Investigated for Tb
(N = 742) (N, column %)
NTM positive
(N = 19) (N, row %)
OR (95%CI) **
Tb symptoms
no 530 (71%) 15 (2.8%) 1*
yes 180 (24%) 4 (2.2%) 0.85 (0.28, 2.58)
missing 32 (4.0%)
Nutritional status at admission
healthy 379 (51%) 8 (2.1%) 1*
at risk 195 (27%) 6 (3.0%) 1.48 (0.51, 4.32)
MAM 113 (15%) 2 (1.8%) 0.84 (0.18, 4.03)
SAM 40 (5%) 3 (7.5%) 3.73 (0.95, 14.7)
missing 15 (2%) 8 (2.1%)
* 1 = set as the reference
** Odds of being NTM case among those investigated for presumptive TB
MAM = moderate acute malnutrition, SAM = severe acute malnutrition
Table 2b | Comparative clinical characteristics for those investigated for presumptive TB and infants with NTM 
isolated (continuous variable)
categories Investigated for Tb
(N = 742) (N, column %)
Mean age
(95% CI)
Rank sum p-value /
t-test p value
NTM negative 718 9.34 (8.95, 9.74) 0.20




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The proportion of NTM in pulmonary samples of presumptive TB cases in this infant cohort was rela-
tively low (2.6%; 95% CI 1.5, 3.8). Standard sputum decontamination procedures were judiciously 
applied, hence it is unlikely that NTM yield was affected by this. A similar study among infants in 
Uganda and South Africa found 3.7% (14) and 6% (13) respectively. The epidemiology of exposure 
in this region could be non-linear, where exposure in early childhood is minimal but increases rapidly 
in adolescents. A significantly higher proportion of NTMs were identified among presumptive TB 
cases in an adolescents in the study area (37.5%), at the time of the study (V. Nduba, Personal com-
munication). Nevertheless, the Mozambique cohort and a survey in Ethiopia had more NTMs (15, 
20), and the average prevalence in African adult pulmonary samples was 7.5% in a systematic review 
(10). It is possible that BCG is protective against NTM colonisation. A twenty year retrospective study 
of NTM notifications in children demonstrated increased odds of NTM disease when universal BCG 
vaccination was halted in Finland (4). Therefore, BCG could also protect against colonisation. This 
can be evaluated conclusively in head to head comparisons of BCG and recombinant BCG vaccines 
presently in phase III clinical trials (21).
colonisation or NTM disease / clinical relevance
We did not find statistically significant differences in baseline characteristics between NTM cases and 
other presumptive TB patients suggesting widespread exposure across the study population. There 
were no differences in the clinical or radiological characteristics between presumptive TB and NTMs 
cases.
NTM disease is clinically and radiologically indistinguishable from TB (9). Two NTM cases 
were symptomatic with a suggestive radiological picture and would have qualified as NTM disease, 
but MTBC was also isolated from their sputum. The remainder had no combination of suggestive 
clinical or radiological features. We therefore conclude the NTM cases represent colonization. There 
is a possibility that these are laboratory contaminants, however this is unlikely since we checked for 
contaminants by having negative controls.
Risk factors - environmental exposure
We did not identify any environmental risk factors for NTM incidence. Unlike MTBC which is 
transmitted from person to person, NTM transmission occurs via repeated environmental exposure. In 
infants this would be through handling by parents and siblings. The study area is rural. Risk for acquir-
ing NTMs is significantly higher in communities engaged in occupations that generate aerosols and are 
exposed to soil for prolonged periods such as agriculture (22). It is not clear what the environmental 

































Risk factors - host factors
Host factors predisposing to NTM isolation were inter-current MTBC disease and severe undernutri-
tion, although the latter did not reach statistical significance. Past history of TB has been known 
to be a risk factor for NTM disease (23, 24); since we studied infants that could not be confirmed. 
Interestingly, in this study, MTBC isolation increased the odds of NTM isolation almost fifty fold. 
NTM-MTBC co-infection in the same infant host has been observed (13, 15), and in adults in high 
TB burden countries (25). TB appears to be a pre-existing lung condition predisposing to NTM 
colonisation (9).
Low Body Mass Index and poor nutrition are other possible host factors, even predicting risk of 
disseminated NTM disease in other studies (26, 27), our study seemed to show the same trend.
Only in one case was the NTM case HIV infected, indicating among infants in this region, im-
munodeficiency is not a factor in NTM isolation in sputum.
NTMs isolated
The spectrum of organisms identified in this NTM study are in type and frequency to those reported 
in Uganda (14), Ethiopia (20), and Saudi Arabia (24). M. fortuitum was most frequently isolated in 
these studies. There could be geographic and climatic factors in the distribution. All the regions have 
warm climates. Increase in latitude and polarity has been shown to be associated with higher isolation 
rates of more pathogenic, slow growing mycobacteria (4, 13, 15).
Tb diagnostics
There was no detectable difference in TST positivity between NTM cases and other patients whereas 
NTM sensitization is known to be responsible for false positive TST readings. Indeed false positive 
TSTs due to NTMs are infrequent and mainly relevant in areas with low TB endemicity (28).
bcG efficacy
NTMs influence the relative efficacy of BCG vaccines (29). The nature and type of NTM isolated in 
TB endemic countries are critical to an efficient vaccination campaign (2). The relative frequency of 
isolated species may correlate with the prevalence of skin sensitivity to their antigens, as was shown 
in Malawi (11). RGMs have been shown to be protective against leprosy and TB (11). This could 
not be confirmed in the current study due to the low numbers of NTM isolated. As there was no 
unvaccinated control group, it is not possible to assess efficacy of BCG. Thus, it appears that the risk 
of exposure to NTM as a covariate of vaccine efficacy as has been previously suggested, is quite low in 
the target age group.
limitations
Our analysis was limited due to the small proportion of NTMs isolated in this age group. Nevertheless, 
it forms a baseline assessment for future studies including future vaccine trials. Also, not all infants 







from children without presumptive TB. Therefore, the NTM incidence may be an underestimate of 
the NTM burden in the population.
cONclusION
This study has attempted to document the incidence of NTM among infants thought to have TB. 
The clinical relevance of NTMs isolated points to colonisation and not disease, as all the infants from 
whom NTMs were isolated did not meet the ATS criteria for disease. Our data shows that a patient 


































 1. Primm TP, Lucero CA, Falkinham JO, 3rd. Health impacts of environmental mycobacteria. Clin Microbiol 
Rev. 2004;17(1):98-106.
 2. Jenkins AO, Michel A, Rutten V. Original Mycobacterial Sin, a consequence of highly homologous anti-
gens? Vet Microbiol. 2017;203:286-93.
 3. Lake MA, Ambrose LR, Lipman MC, Lowe DM. ‘”Why me, why now?” Using clinical immunology and 
epidemiology to explain who gets nontuberculous mycobacterial infection. BMC Med. 2016;14:54.
 4. Kontturi A, Soini H, Ollgren J, Salo E. Increase in Childhood Nontuberculous Mycobacterial Infections 
After Bacille Calmette-Guérin Coverage Drop: A Nationwide, Population-Based Retrospective Study, 
Finland, 1995-2016. Clin Infect Dis. 2018;67(8):1256-61.
 5. Zimmermann P FA, Curtis N. Does BCG vaccination protect against Nontuberculous Mycobacterial 
infection? A systematic review and meta-analysis. Journal of Infectious Disease. 2018;218:679-87.
 6. O’Brien DP, Jeanne I, Blasdell K, Avumegah M, Athan E. The changing epidemiology worldwide of 
Mycobacterium ulcerans. Epidemiol Infect. 2018:1-8.
 7. Loftus MJ, Tay EL, Globan M, Lavender CJ, Crouch SR, Johnson PDR, et al. Epidemiology of Buruli 
ulcer infections, Victoria, Australia, 2011-2016. Emerg Infect Dis. 2018;24(11):1988-97.
 8. Mangtani P N-DP, Keogh RH, Sterne JAC, Abubakar I, Smith PG, Fine PEM, Vynnycky E, Watson JM, 
Elliman D, Lipman M, Rodrigues LC. The duration of protection of school-aged BCG vaccination in 
England: a population-based case-control study. Int J Epidemiology. 2018;47:193-201.
 9. Lopez-Varela E, Garcia-Basteiro AL, Santiago B, Wagner D, van Ingen J, Kampmann B. Non-tuber-
culous mycobacteria in children: muddying the waters of tuberculosis diagnosis. Lancet Respir Med. 
2015;3(3):244-56.
 10. Okoi C, Anderson STB, Antonio M, Mulwa SN, Gehre F, Adetifa IMO. Non-tuberculous Mycobacteria 
isolated from Pulmonary samples in sub-Saharan Africa - A Systematic Review and Meta Analyses. Sci Rep. 
2017;7(1):12002.
 11. Fine PE, Floyd S, Stanford JL, Nkhosa P, Kasunga A, Chaguluka S, et al. Environmental mycobacteria 
in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol Infect. 
2001;126(3):379-87.
 12. Buijtels PC, van-der-Sande MA, de-Graaff CS, Parkinson S, Verbrugh HA, Petit PL, et al. Nontuberculous 
mycobacteria, Zambia. Emerg Infect Dis. 2009;15(2):242-9.
 13. Hatherill M, Hawkridge T, Whitelaw A, Tameris M, Mahomed H, Moyo S, et al. Isolation of non-
tuberculous mycobacteria in children investigated for pulmonary tuberculosis. PLoS One. 2006;1:e21.
 14. Asiimwe BB, Bagyenzi GB, Ssengooba W, Mumbowa F, Mboowa G, Wajja A, et al. Species and genotypic 
diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis 
in rural Uganda. BMC Infect Dis. 2013;13:88.
 15. Lopez-Varela E, Garcia-Basteiro AL, Augusto OJ, Fraile O, Bulo H, Ira T, et al. High Rates of Non-
Tuberculous Mycobacteria Isolation in Mozambican Children with Presumptive Tuberculosis. PLoS One. 
2017;12(1):e0169757.
 16. Odhiambo FO, Laserson KF, Sewe M, Hamel MJ, Feikin DR, Adazu K, et al. Profile: the KEMRI/CDC 
Health and Demographic Surveillance System--Western Kenya. Int J Epidemiol.41(4):977-87.
 17. Kaguthi G, Nduba V, Nyokabi J, Onchiri F, Gie R, Borgdorff M. Chest Radiographs for pediatric a TB 
Diagnosis: Interrater Agreement and Utility. Interdiscip Perspect Infect Dis. 2014;2014:291841.
 18. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA 
statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir 







 19. Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the 
BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical 
second-line drugs and newer antimicrobials. J Clin Microbiol. 2006;44(3):688-92.
 20. Workalemahu B, Berg S, Tsegaye W, Abdissa A, Girma T, Abebe M, et al. Genotype diversity of Mycobac-
terium isolates from children in Jimma, Ethiopia. BMC Res Notes. 2013;6:352.
 21. Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, et al. The Recombi-
nant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. Front Immunol. 
2017;8:1147.
 22. Hamada S, Ito Y, Hirai T, Murase K, Tsuji T, Fujita K, et al. Impact of industrial structure and soil exposure 
on the regional variations in pulmonary nontuberculous mycobacterial disease prevalence. Int J Mycobac-
teriol. 2016;5(2):170-6.
 23. Simons S, van Ingen J, Hsueh PR, Van Hung N, Dekhuijzen PN, Boeree MJ, et al. Nontuberculous 
mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis. 2011;17(3):343-9.
 24. Varghese B, Memish Z, Abuljadayel N, Al-Hakeem R, Alrabiah F, Al-Hajoj SA. Emergence of clinically rel-
evant Non-Tuberculous Mycobacterial infections in Saudi Arabia. PLoS Negl Trop Dis. 2013;7(5):e2234.
 25. Chien JY, Lai CC, Sheng WH, Yu CJ, Hsueh PR. Pulmonary infection and colonization with nontubercu-
lous mycobacteria, Taiwan, 2000-2012. Emerg Infect Dis. 2014;20(8):1382-5.
 26. Ikegame S, Maki S, Wakamatsu K, Nagata N, Kumazoe H, Fujita M, et al. Nutritional assessment in 
patients with pulmonary nontuberculous mycobacteriosis. Intern Med. 2011;50(21):2541-6.
 27. Fujita M, Kikuchi T. [Immunological background on non-tuberculous mycobacteriosis]. Kekkaku. 
2013;88(12):797-814.
 28. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect 
of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192-204.
 29. Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al. BCG-induced increase in 
interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the 
UK: two randomised controlled studies. Lancet. 2002;359(9315):1393-401.
 30. Demangel C, Garnier T, Rosenkrands I, Cole ST. Differential effects of prior exposure to environmental 
mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing 
RD1 antigens. Infect Immun. 2005;73(4):2190-6.
 31. van’t Hoog AH, Laserson KF, Githui WA, Meme HK, Agaya JA, Odeny LO, et al. High prevalence of 
pulmonary tuberculosis and inadequate case finding in rural Western Kenya. Am J Respir Crit Care Med. 
2011;183(9):1245-53.
 32. Waako J, Verver S, Wajja A, Ssengooba W, Joloba ML, Colebunders R, et al. Burden of tuberculosis disease 
among adolescents in a rural cohort in Eastern Uganda. BMC Infect Dis. 2013;13:349.
 33. Claassens M, van Schalkwyk C, den Haan L, Floyd S, Dunbar R, van Helden P, et al. High prevalence of 
tuberculosis and insufficient case detection in two communities in the Western Cape, South Africa. PLoS 
One. 2013;8(4):e58689.
 34. Auld AF, Mbofana F, Shiraishi RW, Alfredo C, Sanchez M, Ellerbrock TV, et al. Incidence and determi-





Development of a tuberculosis vaccine trial 
site in Africa and lessons from the Ebola 
experience
Grace Kaguthi, Videlis Nduba, Prisca. Rabuogi, Douglas Okelloh, Samuel.G Ouma, 
Gretta Blatner, Sebastian Gelderbloem, Ellen Mitchell, Cherise P. Scott, Suzanne Verver, 
Tony Hawkridge, Jurriaan. E.M. de Steenwinkel, Kayla. F. Laserson, Jan Hendrik 
Richardus















































Tuberculosis is the deadliest infection of our time, with about 1.3 million deaths in 2017. In contrast, 
about 11,000 people died of Ebola between 2014 and 2016. Despite this manifest difference in 
mortality, there is now a licensed vaccine with up to 100% efficacy against Ebola. The developments 
that led to the trialing and licensure of the Ebola vaccine were historic and unprecedented. The single 
licensed TB vaccine (BCG) has limited efficacy. There is a dire need for a new, more efficacious TB 
vaccine. In order to license and deploy such vaccines, trials are needed in a limited number of sites that 
combine high disease incidence, research infrastructure and expertise. We first chronologically describe 
our twelve-year experience in building a TB vaccine trial site, an arduous and incremental process in 
contrast to the recent Ebola outbreak, which illustrates that sites can be set up under great adversity. 
Due to the striking differences in the vaccine development of the two diseases, we also compare the 
number of respective human trials between the two diseases, using publicly available data. Relative to 
the Ebola pipeline, TB vaccines have fewer trials and a paucity of government and industry led trials. 
While acknowledging pathogens have varying levels of difficulty in the development of new vaccine 
candidates, there yet appears to be greater interest in funding and coordinating Ebola interventions. 
We are convinced that TB is a global threat that requires similar concerted effort for elimination.
INTRODucTION
Tuberculosis (TB) is a blight to the technological advances of the 21st century. A global blueprint to 
combat it has been outlined in the end TB Strategy (1). New drugs, diagnostics, and vaccines are 
in development with the goal of elimination. For external validity and generalizability, trial sites in 
endemic areas are needed to advance the various candidates through phase III licensure trials. Many 
countries with a high burden of TB are infrequently set up to conduct clinical research. These chal-
lenges hinder advancement of TB vaccine candidates.
From 2014 to 2016, there was an outbreak of the Ebola virus in West Africa. Outbreaks had been 
documented periodically from 1976, with case fatalities of 90%. However, in the recent outbreak, the 
risk of widespread contagion from global travel and its potential for bioterrorism, prompted strong 
responses. In a highly entropic environment, 13 prophylactic vaccines were in clinical studies with at 
least 40% evaluated on the African continent between 2014 and 2015 (2). This demonstrated that 
under sufficient threat, the global community can mobilize resources and overcome adverse circum-
stances. Determining vaccine efficacy during an unpredictable outbreak, in low resourced settings 
for an acutely lethal disease is singularly difficult. However, there is now a vaccine, with up to 100% 
efficacy. (2).
In light of these unusual events, we compare the TB and Ebola vaccine development in two ways. 
Firstly, we chronologically narrate our experience and learning in building a TB vaccine trial site from 
the ground up. Thereafter, we compare this with the site set-up process for Ebola vaccine trials. Finally, 
we review the number of clinical vaccine trials for both diseases, by phase and funding, from 2014 







experiences in relation to current and future TB vaccine trial sites and places our perspectives on TB 
vaccine development in the context of the Ebola outbreak.
Tb vaccine trial site development
Study area and study population
Our reflections are based on studies conducted from 2007 to 2019 at a site in Siaya county, Western 
Kenya (Figure 1). The area is rural, 400km west of the capital Nairobi. The population mostly com-
prises peasant farmers. There is a high but declining prevalence of TB, HIV and malaria (3). Part of 
the study area was under health and demographic surveillance (HDSS), tracking births, deaths, and 
migrations.
site history and development
In 2007, a consortium received a European and Developing Countries Clinical Trials’ Partnership 
(EDCTP) grant to create capacity necessary for TB vaccine trials. Two epidemiological TB studies in 
adolescents and infants were conceived. At the time, there was little research infrastructure. A collabo-
ration with the then Siaya Hospital was set up. Additional training for nurses on TST administration 
and reading, collection of induced sputa and gastric aspirates was provided by a team from a sister site. 
Study staff were extensively trained in collaboration with the Vienna School of Clinical Research on 
(among others) biostatistics, research methods, ethics, Good Clinical Practice (GCP), and trial site 
management. Also, several site staff received concurrent sponsorship for MSc’s and PhD’s.
Tuberculosis studies
We describe five TB studies conducted serially at our site and the lessons learnt in each.














































1. adolescent cohort study (acs)
The ACS began in 2007, with the objective of recruiting adolescents to establish the optimal way 
to access them in the study area and determine TB prevalence and incidence in preparation for TB 
vaccine trials. A mobile field site (MFS) was used to enroll adolescents. The MFS was a collection of 
tents, a mobile radiography unit and mobile generator pitched in a grassy open field in a school, church 
compound or other open public arena (Figure 2).
Potential MFS sites were identified by study staff, and the site assembled every week. The tents 
housed study staff, parents and adolescents who moved serially from consenting, TB symptom screen-
ing, TST administration or reading, to chest radiography and then to dispatch. Data entry was on Per-
sonal Digital Assistants and laptops, using a local area network powered by the mobile generator. Upon 
exhausting all potentials at that catchment area, the site would demobilize and set up in a contiguous 
site and the process would start over again. Follow-up visits were conducted in similar fashion. The 
challenges of operating in an open field were particularly apparent during the rainy seasons. The site 
would get flooded or barely accessible, disrupting study processes. In that case it would be disassembled 
and relocated. A total of 5004 adolescents were recruited on target over 12 months and 83% retained 
(4). Most of this team rolled over into the infant study.
2. Infant cohort study (Ics)
Paediatric TB estimates from program data were not age-disaggregated, masking the disproportionate 
affliction of young infants with TB. In 2008, the thinking of the TB vaccine community leaned heavily 
towards infants as a target population. Therefore, the ICS was conceived to provide estimates of TB 







incidence using comprehensive diagnostic methods (Nduba V, 2019-submitted), and to demonstrate 
capacity to deliver BCG within 96 hours of birth. This was to anticipate the administration of BCG 
replacement candidate vaccines.
At the time, it was reported that 80% of mothers delivered at home, with the help of a traditional 
birth attendant (TBA). We engaged TBAs to assist in notifying births to the study staff. The recruitment 
coordinator would then dispatch a nurse on a motorbike to perform enrolment procedures. Thereafter, 
a nurse would deliver BCG to enrolled infants. The median age of enrolees was 10 days, therefore in 
many cases it was not possible to deliver BCG within 96 hours of birth due to late notifications and 
problems locating mothers who were highly mobile in the study area. This was accentuated when due 
to insufficient notifications, the study area was extended to Boro, a nearby sub-county, which was not 
under the HDSS. In addition, the terrain was frequently challenging. Nurses were inexperienced mo-
torbike riders and predominantly female. There were several falls that injured their morale more than 
anything. Nevertheless, the team rallied, and 2900 infants were enrolled on target within 12 months.
Fortunately, the number of home births in the study area continued to decline. By 2011, at least 
40% occurred at health facilities (5). Future trials of BCG replacement vaccine trials can therefore 
enrol infants at health facilities.
The ICS operated out of two tents in a grassy field of the Siaya Hospital, seeing scheduled and un-
scheduled visitors. The hospital allocated a store in the paediatric ward for creation of a negative pressure 
room for specialized sputum collection procedures. We renovated a defunct, dilapidated amenity wing 
designed for private patients, and converted into a case verification ward for overnight admissions for 
TB investigation procedures. The existing hodgepodge of facilities did not meet trial requirements, as 
there was no GCP compliant pharmacy, archival facilities, or laboratories. Therefore, in 2009, construc-
tion of a state-of-the-art research annex (Figure 3) with all the requisite infrastructure at the hospital 
grounds began, funded by several partners. It was completed in 2012 and auspiciously launched.














































The study also created a previously non-existent capacity to diagnose paediatric TB using induced 
sputa and gastric aspirates as well as structured chest radiograph review. There were thousands of 
ancillary care visits that contributed the largest number of presumptive TB cases, given the non-specific 
presentation of TB in infants.
3. aeras-402 (Nochak)
The first TB vaccine trial at the site followed closely on the heels of the ICS. It was a phase IIb trial 
of AERAS 402 in healthy, HIV uninfected, BCG vaccinated infants (6). The site was the first to be 
initiated into the trial in 2010. The study team was now proficient in recruitment of infants and 
requisite community links had been forged. There was widespread enthusiasm for study participation 
due to intense community mobilization by site staff. Locals had branded the study ‘NoChaK’ (Nonro 
mar Chanjo mar Kahera), translated ‘a new TB vaccine’ in Luo, the local language (Figure 4).
Disappointment ensued when there was an inordinate number of screen failures due to abnormal 
biochemistries, particularly elevated total bilirubin in infants who were in every other sense healthy. 
To determine eligibility, the National Institutes of Health (NIH) reference ranges were used, which, in 
hindsight, were clearly derived from a distinct population. It would have been unethical to continue 
screening, and therefore enrolment was paused to investigate the issue. To exclude invalid laboratory 
results, the local laboratory that was also being used for the RTS,S malaria vaccine trial, was scrutinized 
to determine the reproducibility and repeatability of affected parameters, as well as External Quality 







Assurance (EQA) program results. The laboratory cleared. We found no antecedent literature describ-
ing what we were observing. Following wide consultations, we developed a new set of reference ranges. 
This allowed the study to proceed with enrolment. The area was hyper endemic for malaria and that 
was considered the prime reason for the elevations in healthy infants. Years later, two publications 
emerged on the subject, but for an adult population proximal to the study area, which mirrored our 
observations (7, 8).
There were significant problems with collection and processing of Peripheral Blood Mononuclear 
Cells (PBMCs). The cells needed to be separated and frozen within 4 hours of collection. The study site 
was about 80 km away (about 1.5-hour drive) from the immunology laboratory, with predictable inac-
cessibility in wet weather. The process of separation took at least two hours. In addition, eight ml of 
blood were collected in several tall vials. Like many African communities, there were strong sensitivities 
to blood sampling, despite our best efforts to explain that the relative blood volumes sampled would 
not adversely impact the babies given their age and weight. Furthermore, as infants were significantly 
dark skinned and healthy, if more than one attempt was needed to collect these samples, parents 
would get distressed and the time taken also derailed the tight separation timelines. In response, tight 
orchestration of the visits with PBMC collection was done. An experienced phlebotomist, efficient in 
cutting down the collection time was added to the team. Technicians were alerted once the sample left 
and were on stand-by ready to immediately begin to process the samples.
Unfortunately, the laboratory team had no prior immunology experience. They failed proficiency 
testing, some on more than one occasion and this skill was only gradually acquired. In addition, on 
one occasion the dry ice shipper containing EQA samples arrived at the destination laboratory dry, 
compromising cell viability. The laboratory teams were retrained, and this capacity was then available 
for the future trial among adults.
The stability of AERAS 402 vaccine at 2-8 degrees was short-lived. It was stored at -80 0C in a 
research pharmacy in Kisumu (Figure 5).
Dbs: Dry blood spot, PbMc: Peripheral blood Mononuclear cells
Twenty-four hours prior to dosing, it would be transferred from the freezer to the refrigerator and 
could keep for only six weeks. There were frequent power outages at the clinic, therefore it was not 
possible to safely keep vaccine on site. Therefore, an alternative thaw protocol was used. Vials would be 
removed from the freezer, thawed at room temperature for one to two hours, and then shipped to site 
under rigorous temperature monitoring. After review of potential participants, the study doctor would 
call up the vaccine from the central pharmacy, and vaccinations would happen upon arrival two hours 
later. As there were mandatory post-vaccination observation procedures, many mothers were dropped 
off at their homes late in the night, which created friction in families. Mothers agreed to assemble for 















































The second vaccine trial in this site was a phase IIb trial of M72/AS01E against placebo (9). The site’s 
successful experience with the MFS made it a compelling recruitment strategy for this trial. A total of 
538 individuals were randomized over a period of eight months. The laboratory was now experienced 
in handling immunology samples and there were few hitches.
5. VPM1002
In 2018, towards the end of the M72 study, our site was selected to participate in a phase III trial 
of VPM1002 against BCG among infants. The cumulative site experience in immunology, infant 
recruitment, TB case detection, and adverse event surveillance continues to be applied for this trial. 
Recruitment is expected to end by the second quarter of 2022, with a minimum follow-up time of 12 
months.







lessons from site development
1. Importance of epidemiological studies
The epidemiological studies seriously enhanced our capacity to perform future trials with increasing 
ease and excellence. Increasingly, funding pressures have constrained the space for epidemiological 
studies, as they offer knowledge with no prospects of ‘return on investment’. The placebo arm is 
sometimes viewed as the epidemiological understudy. The trial population, however, is usually a 
selected sub-group that are healthier, HIV uninfected, and probably more accessible to the research 
team based on their different health seeking behaviour. Being subjects of intense health monitoring, 
they likely have lower risks of TB acquisition. The placebo arm therefore provides little context for the 
interpretation of trial results, which are rarely linear or straight-forward. Therefore, epidemiological 
studies should not be considered optional.
2. biobanking inclusivity
Health research capacity building is not without power relations (11). Biobanking is a part of virtually 
every TB vaccine trial. However, once samples are shipped to central laboratories in Western Europe 
or North America, research teams have no say in the deployment of those assays, even while they made 
great efforts to collect them. It is intellectually impoverishing; research teams having the derogatory 
epithet ‘sample traffickers’. In hindsight, a biobanking capacity-building component should have been 
included in the initial studies, creating the legal and scientific framework to ensure democratization 
and inclusivity.
ebola site development
Having reflected on the development of our TB vaccine site, we turn our attention to the development 
of sites during the Ebola outbreak. As Ebola mortality increased during the 2014 outbreak, promising 
vaccine candidates stuck in preclinical phases for years (2, 3) due to lack of funding or interest, were 
fast-tracked into human trials (12-14). Clinical trial protocols were ready within weeks. Ethical and 
regulatory reviews were turned around in two weeks (15). Preliminary efficacy results were availed 
in unprecedented time for rapid decision making (16). The transition to Phase II/III studies was 
unmatched, at eight months, instead of ordinarily one to three years (17, 18) after initiation of the 
phase I study (2).
To have any hope of demonstrating efficacy, the studies needed to be initiated before the unpredict-
able outbreak ended. However, most study areas were unmapped, and lacked electricity and basic 
amenities. In some places years of civil war had destroyed health infrastructure. Scores of health 
workers had lost their lives in the outbreak (19), and those who remained were involved in emergency 
response to victims. Thus, local trained research teams were virtually non-existent (20), as were any 
‘clinical research sites’ (15, 20). Despite all this, the necessary facilities were put up on the go, and 














































The World Health Organization (WHO) was pivotal in overcoming all the challenges by fostering 
interactions with scientific, ethics, regulatory, industry and funder groups from every continent (16). 
Evidently, with high stakes, absent infrastructure or research teams are not obstacles to trial implemen-
tation or success. Further, most countries with high TB burden have significantly fewer barriers to trial 
set-up compared to those setting up Ebola trials.
lessons for Tb vaccine trials from ebola
The trialing and availability of a highly efficacious vaccine for Ebola in an extraordinarily short amount 
of time, led us to compare the vaccine pipelines, the relative numbers of clinical trials, vaccination 
strategies as well as the theoretical probability of success for each disease.
1. Vaccine trial pipeline
Table 1 shows the trials initiated for Ebola versus TB vaccines in the last five years when Ebola vaccine 
trials entered the clinical phase.
We assume that a disease’s vaccine pipeline is a proxy for intensity of research and that a diverse, 
robust pipeline is more likely to produce a candidate that shows efficacy (21, 22). The TB vaccine 
pipeline has fewer studies than doe Ebola and there is also under-representation of government and 
industry sponsored trials. The economic cost of each epidemic makes a compelling case for both 
industry and government involvement. Economic losses, in West Africa and globally, were estimated 
at USD 18 billion as a result of the 2014-2016 outbreak (23). The annual societal cost alone of TB is 
USD 19 billion (24). The WHO has supported TB vaccine initiatives (22), but the Ebola outbreak 
showed us that much more is possible, especially in solving macro-level problems and mobilizing 
resources, probably even in sponsoring trials (16).
As of September 2019, there were only eight preclinical vaccine candidates for TB (www.tbvi.eu/
what-we-do/pipeline-of-vaccines). A main reason for this, other than minimal public interest in ac-
celerating a new TB vaccine, is funding restrictions (25). As a result, stage-gate criteria have been 
developed to constrict the movement of candidates from one phase to the next, with the idea of 
advancing only the most promising candidates, defined largely by available immunogenicity, efficacy, 
and safety data (21, 26). At most of the early stage gate points, particularly pre-clinical to clinical, and 
Phase I to Phase IIb, the candidate has the least possible ‘value chain’ defined as the accumulation of 
value due to demonstrated safety or efficacy or both (27).
Furthermore, immunogenicity criteria (26) that quantify vaccine-induced immune responses may 
not represent protection against disease. These criteria may be flawed, leading to false negatives or posi-








2. Probability of success of a vaccine trial
The difficulty in vaccine design differs from pathogen to pathogen. The average vaccine requires a 
clinical development timeline of 10.7 years and has a market entry probability of 6% (27). Table 2 
shows selected requirements thought to impact the feasibility of accelerated vaccine development. My-
cobacterium tuberculosis is considerably more complex, with great capacity to evade host immunity 
(28). Also, animal models that closely mimic human disease are better for Ebola virus than TB. Hence 
a new TB vaccine could be termed ‘unprecedented’ and the odds of success are pegged considerably 
lower than for most other diseases (29). These estimates are valid but are based on past experience with 
limited government and industry involvement and a minimal global effort.
3. Vaccination strategies and phase II/III trial sites
Ring vaccination in the Guinea Ebola vaccine trial provided preliminary efficacy data in a highly 
dynamic outbreak (2). The most at risk persons were singled out for vaccination, as opposed to vac-
cinating an entire community. There are irrefutable data on asymmetries of TB risk (‘TB hotspots’) 
(40) based on residence (urban vs. rural) (41, 42), certain geographic locations including prison (43) 
and mines (44, 45), social class interactions (46), and age (47, 48). Such epidemiological data have not 
been applied in selecting trial populations for phase IIb-IV trials, yet they would critically minimize 
sample sizes, guide site selection and provide rapid answers as to a vaccine’s efficacy. This was one of 
the pathways explored in the Ebola outbreak.
Table 1 | Ebola versus TB vaccine candidate pipeline from 2014 (WHO Vaccine Pipeline Tracker (www.who.int) 
accessed 12 Oct 2019). (Some trials have more than one sponsor)
ebola vaccine trials Tb vaccine trials
Total clinical trials 60 30
Phase 1 34 13
Phase 2 16 10
Phase 3 8 6





Government sponsors 17 3
Russia (MoH) 3 1
China (Jiangsu Province) 3 0

















































We have described our incremental 12-year process of site development, in contrast to an acute, 
chaotic and very productive process in the Ebola virus outbreak. Since the ACS in 2007, about a dozen 
other phase II and III trials have been conducted at our site. Subsequent studies have found better 
infrastructure, more highly experienced teams, and the complexity of protocols implemented at the 
site has also increased. Nevertheless, the end goal is a new efficacious TB vaccine brought to bear on 
the epidemic.
TB unlike Ebola has a lower case fatality, slower epidemic, and lower potential for bioterrorism. But 
its total mortality is hundreds to thousands of times higher. It is our view that developing a new TB 
vaccine will also require centralized coordination of efforts.
The TB vaccine pipeline is plagued not simply by funding limitations, but by an inadequate number 
of ‘hands on deck’. The Ebola crisis calls for a sense of urgency towards the TB epidemic, and for a 
narrowed focus. For example, the lack of knowledge of correlates of protection has not prevented the 
advancement of a new malaria, polio (50), or Ebola vaccine (51, 52), neither the eradication of small 
pox (49). Funds can be prioritized for pre-clinical development and field testing of candidates in order 
to stop the scourge, else the goal of TB elimination will remain elusive (1). Given an Ebola vaccine was 
evaluated and licensed under extreme conditions, it is a rallying call for the TB vaccine community to 
champion the cause.
Table 2 | Feasibility of accelerated vaccine development (Institute of Medicine (US) committee on issues and 
priorities for new vaccine development (30)
Requirement ebola (ref ) Tuberculosis (ref )
Knowledge of clinical signs and symptoms of the disease
to allow differentiation from similar syndromes
+ ++
Knowledge of pathogen characteristics: strains / serotypes,
infectivity / virulence, antigenicity, immunogens
++ (31) ++ (32, 33)
Ability to cultivate pathogen + (34) ++
Identified non-human models of infection,
closely mimicking human disease
+++ (35) ++ (36)
Knowledge of human immune response to the pathogen
(duration, type of response)
+ (37) + (38)
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The overall aim of this thesis was to determine the suitability of infants as a trial population and inform 
diagnostic considerations for future TB vaccine trials. This thesis also documents the practical experi-
ence of site set-up and trial implementation in Kenya as well as the lessons for TB vaccine development 
following the successful trial of a new vaccine against Ebola virus. These questions have been addressed 
in TB cohort studies particularly among infants.
In the discussion, I review the principles for selecting a trial population, grouped into trial related 
factors and post-trial considerations using an infant population. Thereafter, I review epidemiological 
principles that can guide selection of other possible target populations considering disease patterns in 
endemic countries. This is followed by an appraisal of the chest radiograph as a diagnostic tool in trials. 
I discuss the role of Non-Tuberculous Mycobacteria in TB vaccine trials, as concerns TB diagnosis. 
Furthermore, I chronicle the lessons learnt in site development and examine the current pipeline 
of candidate vaccines targeting infants. Finally, I provide possible future perspectives, and provide a 
conclusion to the thesis.
The specific research questions addressed in this thesis are grouped thematically as follows:
The suitability of infants as a target population.
1. To assess TB incidence, post-neonatal mortality and cohort retention among infants.
2. To evaluate the chest radiograph (CXR) for its suitability as an endpoint for infant trials where 
paucibacillary disease is most frequent.
3. To determine the clinical relevance of non-tuberculous mycobacteria (NTM) isolated in sputum, 
given their ubiquity and their indistinguishable case presentation to TB disease.
4. To reflect on the lessons learnt in building a new TB vaccine site and review the TB vaccine 
development pipeline in the context of the Ebola virus outbreak.
ad 1: selecting a target population: Infants as a trial population. The selection of a target population 
requires consideration of multiple factors. I classify them into those related to trial implementation and 
those that concern post-trial roll-out.
1. Trial Implementation Related factors
1a. Sample size calculations: Incidence, recruitment, retention, mortality
First, I compare trial efficiency of infant studies with adult/adolescent studies, computed using estimates 
of incidence, retention and mortality from an infant cohort study. The incidence of microbiologically 
confirmed TB among young children in our cohort study was high, at 0.28 per 100 person years of 
follow up. About 80% of the cohort was retained. We showed that in a superiority parallel arm TB 
vaccine trial, assuming definite TB incidence of 0.28 per 100 pyo (Nduba V, submitted), retention of 
80%, vaccine efficacy (VE) of 50% (1, 2), 24,300 infants would need be recruited and followed up 
for three years.
In the recent M72 trial, TB incidence was 0.3% among LTBI positive adults who have higher risks 







for validity, who have lower TB incidence, about 0.15% (3), with 80% power and 50 % VE. Based 
on these estimates about 50,000 healthy adults would be required. Further, larger sample sizes often 
require longer patient accrual times, multiple sites in different locations and complex logistics. All these 
inflate the trial costs (4). By recruiting 2900 infants in twelve months at a single site, we demonstrated 
the feasibility of accruing thousands of infants within a reasonable time frame. Therefore, we conclude 
that the feasibility and greater efficiency of infant trials has been shown.
1b. Mortality
About 7% of the infant cohort died over twenty-four months. The most frequent immediate cause 
of death was hypovolemic shock, while undernutrition was most frequently the underlying cause of 
death. Background mortality provides context for interpretation of vaccine efficacy. For example, 
Mosquirix®, in its phase III trial reduced the number and severity of malarial episodes but surprisingly 
had no impact on mortality (5). This has been attributed to local factors such as co-morbidities which 
drive mortality (6). In addition, as BCG has mortality benefits, all-cause mortality is an important 
secondary endpoint for infant TB vaccine trials. We conclude that baseline infant mortality estimates 
guide the comparisons of vaccine and control (BCG) arms in every site.
1c. Immunological factors: Vaccine design
MTBC is a complex pathogen, extensively evolved to evade and manipulate host immunity (7, 8). On 
the other hand, neonatal immune systems are underdeveloped, lack antigenic experience as a result of 
protected in-utero conditions, have poor immunological memory and heightened immunoregulatory 
responses to facilitate maternal co-existence (9, 10). Therefore, vaccinating adults has been more attrac-
tive. In addition, in high burden countries, maternal infections such as HIV, Malaria and helminths 
influence the development of fetal and neonatal immunity decreasing vaccine responsiveness (11).
2. Post-trial roll-out related factors: Vaccination platforms and impact 
on the epidemic
2a. Ethics
The high TB incidence among infants is further evidence of their higher susceptibility to infection after 
exposure, higher risks of progression to disease given infection and propensity to severe or dissemi-
nated disease (12). From an ethical perspective, infants are particularly vulnerable and need protection 
through an efficacious vaccine.
2b. Vaccination platforms
Vaccination of children is routine and largely accepted. BCG is the most widely administered vaccine 
(13). There are established cold chain infrastructure and implementation mechanisms even in poor 
countries. This infrastructure is currently not available for other target populations. They would likely 








As infants do not transmit disease, the public health impact of a neonatal vaccine would be delayed by 
about a decade (14), when they would become vulnerable. They are therefore secondary in TB control 
efforts. This has been viewed as a major limitation of infant vaccination. A long-term view is needed, as 
has been shown in some modeling studies, the rapid impact on TB burden of vaccinating adults with a 
post-exposure vaccine would plateau, while that of infants would continue to increase (15).
In summary, choosing infants is beneficial for trial efficiency, ethics and post -trial roll out; but has 
limitations of underdeveloped infant immunity and delayed impact on TB case load.
Additional considerations for selecting an adult target population. As infants do not transmit dis-
ease, adults and possibly adolescents must be included as ‘immunisable’ populations. I discuss some 
principles for selecting other target populations based on epidemiological principles and available data.
3. Trial implementation related factors
A way to minimize sample sizes, increase trial efficiency and feasibility, is to target high risk popula-
tions, contrary to the current paradigm which considers all persons living in high burden countries to 
have similar risks of disease acquisition. I discuss the rationale for this, provide real world examples and 
suggestions based on epidemiological data from high burden countries.
3a. 20/80 rule
The 20/80 rule in epidemiology states that 20% of the host population are responsible for at least 
80% of the net transmission potential, as measured by the basic reproduction number R0 (16). The 
consequence of heterogeneity in transmission of infectious agents is the commonly observed clustered 
distribution of infections and disease within the host population, such that few hosts are rapidly, 
frequently or heavily infected while the majority either evade the infection or rarely suffer infection. 
For example, one prisoner was responsible for 63% of incident TB cases in a Brazilian prison (17). 
These have been termed ‘super-transmitters’. They combine high infectiousness with access to many 
casual contacts in congregant settings. It has been observed in different settings that household trans-
mission accounts for <20% of cases (15). Surveys have shown areas of preferential transmission (18). 
Conversely, there are persons who despite repeated MTBC exposure remain IGRA/TST negative, 
termed ‘resistors’ (19, 20). This phenomenon has been observed in several diseases such as Ebola and 
HIV and the underlying factors are not always well characterized (21, 22). The reverse could also be 
true, where 20% of the population are particularly susceptible to acquiring infection and progressing 
to disease following casual contact. As correlates of risk have not yet been identified, using susceptibles 
as a target population has not yet been envisioned.
3b. Heterogeneity of disease burden
The 20/80 principle is exemplified in heterogeneity in TB burden based on spatial and social settings 








In high burden countries, 80% or more of cases can be confined to a particular geographical location. 
In a prospective cohort study of Multi-Drug Resistant (MDR-TB) cases and their household contacts 
in Peru, there was increased risk in specific neighborhoods proximal to a certain health centre and the 
authors argued targeted interventions at areas of concentrated risk would be more useful than a blanket 
approach. (23). Likewise, modeling transmission in 3rd most populated city in all of South America, 
Rio de Janeiro, showed only 6% of cases accounted for 35% of city-wide transmission (24).
3b2. Social heterogeneity
In the same vein, prisons, slums, public transport and health facilities have also been found to be 
hotspots of transmission (25-28). The prevalence rates in these areas are significantly higher than the 
general population regardless of economic status or local TB burden (29). In a recent vaccine modeling 
study using South African data, targeting miners and delivering the vaccine to them at the mines 
averted more TB cases compared to community targeted vaccination (30).
3b3. Wealth assortative mixing
A concept related to social hotspots is that of wealth assortative mixing (31) and is the basis of targeting 
the poor for TB vaccines and other control activities. It is hypothesized that the poor are more likely to 
contact the poor who in turn are more likely to develop disease and transmit it to other poor people. 
Such dynamics increase the R0 and make it more challenging to control disease using a blanket, ‘one 
size fits all’ approach. In India, the poorest quintile of the population had a five-fold disease prevalence 
of that of the wealthiest (1% vs 0.2%). After accounting for poverty associated risk factors (alcohol and 
tobacco use, HIV, diabetes, low BMI), residual variance in TB rates was thought to be due to wealth 
assortative mixing. The authors recommended for equity reasons but also to improve efficiency to 
target the poor for interventions in order to optimize limited resources. It follows that the same should 
be selected as a trial population. There is precedence for targeted interventions in HIV (32-34), cholera 
(35, 36), and malaria (37).
3c. Post-trial access
Adult vaccination would likely struggle to achieve the high coverage observed with neonatal BCG 
vaccination. Vaccination platforms for adults would need to be created. Many high incidence countries 
have poorly funded health systems, overburdened by providing care and treatment. They may not be 
able to develop or sustain the logistical operation of delivering mass vaccination campaigns. Further, 
the acceptability and feasibility of adult vaccination has been taken for granted. As at publication, we 
could not find data on perceptions and acceptability of adult TB vaccination. Vaccine hesitance has 
now been recognized as one of the top ten global threats (17) and could undermine decades of efforts. 








In summary; there is heterogeneity in susceptibility to TB as well as transmission patterns. This 
should be taken into consideration when selecting the target population for efficient vaccine trials and 
consequently for disease control efforts.
ad 2: The chest Radiograph as a diagnostic tool for Tb endpoints
We found low inter-rater agreement on abnormalities consistent with TB on the chest radiograph 
poor; kappa =0.14; (95% CI: 0.10 ‐ 0.18). This and the frequently atypical picture in infants are 
limitations to its use. In another setting with high TB/HIV burden, abnormalities consistent with 
TB on CXR were predictive of culture confirmed TB among hospitalized children (38). One critical 
difference is that hospitalized children would be presenting with advanced disease and likely to have 
more classical features on which most readers would agree. Trials deploy active follow up strategies 
to detect every potential endpoint. This blunts the sensitivity of the CXR, as early disease is detected 
which causes non-specific and subtle radiological changes. Nevertheless, in the trial of MVA85A, odds 
of microbiologically confirmed TB increased two-fold when at least two experts agreed there was 
radiographic TB defined by classical features (39). Therefore, the CXR remains useful for endpoint de-
tection when two or more experts agree on radiological TB. Diagnostics deploying minimally invasive 
samples, such as stool and urine, with high sensitivity and specificity, are needed for young children.
Automated reading of chest radiographs has been used to screen adult patients with presumptive 
TB before further diagnostic evaluation. It has been shown to have similar sensitivity but albeit 
lower specificity compared to expert readers (40, 41). It has not been evaluated in diagnosis in young 
children who have a different radiological pattern of TB. Therefore, its use in trials is presently not 
recommended.
ad 3: Non-Tuberculous Mycobacteria (NTM): clinical Relevance and 
Differential diagnosis for Tb
NTM disease is clinically and radiologically indistinguishable from MTB disease (42). NTM disease 
does not respond to anti-tuberculous therapy. In paediatric studies, composite endpoints are used in 
the absence of microbiological confirmation. Unidentified NTM disease can therefore be a source of 
false positives, given the similar case presentation. However, we found that all NTMs isolated in spu-
tum represented colonisation and not disease. There was also no association between NTM isolation 
in sputum and TST positivity. This could have been due to the small proportion of NTMs isolated. It 
was not a study objective to evaluate the immunological pathways of interaction between TB vaccines 
and NTMs. Their ubiquity in the environment and subsequent presence in the lung microbiome 
implies an immunomodulatory role. This should be evaluated in epidemiological studies and in future 
trials of both infants and adults with a view to define how they interface with host immunity. Induced 
sputum samples should be aliquoted and stored for ribosomal RNA sequencing to explore the role of 
flora in infection, susceptibility and disease. NTM based vaccine of M. obuense showed efficacy in HIV 







ad 4: site development and the Tb vaccine pipeline: lessons learnt
We chronicled the history of the predominant TB vaccine trial site in Western Kenya. Some of the 
challenges encountered with respect to logistics and operations have been observed in other TB vaccine 
trial sites (44, 45). Many were unique to our specific settings such as the lack of reference ranges 
relevant to our population and immunology inexperience.
The TB vaccine pipeline calls for governments, particularly in high burden countries, to prioritize 
contributing to the research and development process, as happened with the Ebola virus outbreak of 
2014-2016.
TB vaccine pipeline targeting infants: The review below shows candidate TB vaccines in which 
infant trials are planned, ongoing or have been completed.
Phase I trials
MTBVAC: MTBVAC is a live attenuated MTBC strain, first of its kind. Genes coding (phoP) for 
transcriptional factors associated with virulence have been deleted (46). A phase IIa dose finding, 
safety and reactogenicity study is underway in infants in South Africa, to be completed by December 
2020. It could have potential for immunocompromised patients, as it showed efficacy despite hyper-
attenuation (47).
HYBRID 56/IC31: Hybrid 56/IC31, is an adjuvanted vaccine currently in Phase I trials in South 
Africa for safety and immunogenicity in BCG primed infants. It contains Rv2660c, an antigen strongly 
recognized by cells of LTBI individuals. The adjuvant is IC31 which is a strong Toll Like Receptor 9 
agonist.
Phase II trials
Phase II trials are the graveyard of new molecular entities particularly vaccines (www.bio.org/clinical-
development-success-rates-2006-2015 accessed Dec 2019) (48-50). Only 31% of candidates progress, 
more frequently for lack of efficacy rather than safety. This contributes significantly to high research 
and development costs (48, 50). I examine the current status for infant vaccines.
MVA85A: MVA85A a modified vaccinia Ankara virus expressing antigen 85A (MVA85A), intended 
as a boost after BCG priming. The vaccine was safe and tolerable intradermal, in preclinical studies, 
and in the phase IIb trial in infants. However, it showed no efficacy against TB (51). The result was 
termed surprising based on preceding animal studies. It was later claimed that the animal efficacy 
results from these studies downplayed negative results. Apparently, macaques vaccinated with BCG 
and boosted with MVA85A had poorer outcomes comparable to those that received no vaccine (52). 
Additionally, there were doubts on the rigor of the pre-clinical studies (51, 53), which are said to 
be geared towards establishing safety for marketing authorization rather than providing evidence of 
efficacy. The authors refuted this (51). The vaccine has recently been reformulated as an aerosol. It 
was safe and immunogenic in a phase I study, for possible further investigation in phase II trials (51).
AERAS 402: Aeras 402 was a replication deficient serotype 35 adenovirus vectored vaccine contain-







intended as a boost after BCG priming. Phase IIb trials were initiated in 2009 in Kenya, Mozambique 
and South Africa. After the dose-finding phase, the predefined immunogenicity target was not met, 
and the trial was terminated for futility (54). The vaccine was broadly immunogenic, however some of 
the reasons for failure were the immunodominance hierarchy elicited by adenoviral vaccination may 
not adequately mimic natural infection, leading to a non-protective immune response (55). Further 
development has stopped.
M72/AS01E: This is an adjuvanted vaccine expressing two Mtb 39A and Mtb 32A present in 
MTBC and BCG, combined with AS01E adjuvant. It has successfully completed Phase IIb trial in 
adults in Kenya, South Africa and Zambia, demonstrating 50% efficacy in preventing disease in LTBI 
individuals (Tait D, 2019). A phase II safety and immunogenicity study among infants was completed 
that demonstrated non-interference with the Expanded Program of Immunization (EPI) schedule, 
safety and satisfactory induction of CD4 T-cell responses. It is not clear whether phase IIb studies in 
infants are planned.
Phase III trials
VPM1002: VPM1002 is a urease C-deficient Listeriolysin expressing BCG vaccine strain. Listeriolysin 
facilitates the perforation of the phagosome membrane, allowing the release of recombinant BCG 
antigens into the cytosol of host cells, and activate appropriate Th1 and Th17 immune responses. The 
deletion of the Urease C gene acts synergistically with the Listeriolysin expression by creating an acidic 
milieu for its action. Its safety and immunogenicity have been assessed in a Phase II trial in South 
African infants (56). A phase III trial with the endpoint of preventing TB infection is underway in 
Kenya, Uganda and South Africa.
fuTuRe PeRsPecTIVes
Immunomics
The most suited trial population would take into account heterogeneity in individual susceptibility, 
and be well characterized by genetic, age and geographic factors. Immune responses would likewise 
accurately predict probability of progression to infection or to disease status after MTBC exposure 
or propensity to an inflammatory immune response which is more damaging to host tissues (7). In 
addition, a-priori knowledge of vaccine induced immunity would then be used to identify the target 
population most likely to benefit from vaccination. This would minimize sample sizes, minimize po-
tentially harmful exposure to the investigational vaccine and maximize benefit, thereby increasing trial 
efficiency. After licensure, it would be cheaper and easier to create tailored platforms for vaccinating 
a small proportion of susceptibles, assuming that outside of neonates and adolescents, vaccination 
platforms would need to be created in the developing world.
This information is largely unavailable, and this remains an aspirational goal that could be achieved 







century approach that combines immunology, genetics, proteomics, transcriptomics and bioinformat-
ics to characterize host -pathogen interactions that is particularly useful for vaccine development for 
complex pathogens such as TB (57).
Such an approach supports a rational approach to vaccine development based on identifying an-
tigenic targets, Correlates of Protection and can unlock the keys to developing vaccines that confer 
lifelong protection.
cONclusION
We sought to determine the most appropriate population for vaccination, review the chest radiograph 
as a diagnostic tool for TB end-points in vaccine trials, the species and clinical relevance of NTMs in 
TB trials and the lessons learnt from a TB vaccine field site in the context of the Ebola outbreak. We 
found that selecting the trial population requires consideration of pre- and post-trial factors, and our 
studies provided data for such decisions. We found the CXR remains a useful diagnostic tool in the 
hands of two or more experts. In addition, we found NTM isolation in sputum of presumptive TB 
patients to represent colonisation and not disease, hence there is apparently no diagnostic dilemma. 
Finally, we described our twelve year experience developing a TB vaccine site and lessons learnt and 
concluded global efforts can be intensified and harmonized if a global coordinator such as the WHO 
were to take lead in the process of bringing a new TB vaccine to the market.
RecOMMeNDaTIONs
1. The most appropriate target population
Under a scenario of unlimited resources, vaccines targeting every high-risk population should be 
developed with the relevant endpoints. These include post-exposure vaccine for adults and adolescents 
(Prevention of Disease or Prevention of Recurrence), or Prevention of Infection for neonates. HIV 
infected persons would also benefit from a safe and effective vaccine as outside of infants, TB mortality 
is highest in this group. In the reality of the current funding scenario, vaccines targeting infants should 
be prioritized, due to the high incidence, the difficulty of diagnosing TB using current tools and the 
subsequent high case fatality of undetected and untreated disease. The second most urgent priority 
is adults in slums or other impoverished rural settings and prisons. From a bioethical standpoint, 
where the benefits outweigh risks, as with TB vaccine trials, and with proper oversight as is the cur-
rent standard practice, research participation of prisoners can be informed, deliberate and voluntary 
(58-60). Further, experts have considered such that there is a tremendous need for scientifically sound 
research among prisoners (58). Vaccine acceptability studies should be done among adults in high 
burden countries to ensure high coverage post-approval. As was observed with the Ebola virus vaccine, 







2. Greater investment in Research and Development by governments
Under the coordination of a global health entity such as the WHO, governments of high burden 
countries can be mobilized to contribute financially or in kind to vaccine research and development 
process. Many of these have reported unprecedented economic growth over the last decade. In kind or 
indirect contributions will also expedite the development process. For example, by removing barriers 
to research including costly tariffs on research equipment, including mandatory research training in 
the curriculum for health workers, thereby enhancing local capacity to conduct trials or by facilitating 
speedy ethical and regulatory review of research protocols.
3. The chest radiograph is still a useful diagnostic tool in trials
The chest radiograph should be included in infant trials with centralized, blinded, expert adjudica-
tion. New diagnostics, including point of care tests with high sensitivity and specificity that utilize 
minimally invasive techniques are needed. In addition to increasing end-point detection for trials, it 
will likely reduce TB mortality.
4. limited autopsies to increase end-point yield in paediatric trials
Techniques for limited autopsies should be part of infant trials, as the causes of death were only 
identifiable in 31% of cases in our study. It is likely that there were TB deaths among these based on 
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Tuberculosis is a major public health problem, with particularly high morbidity and mortality among 
infants. The only licensed TB vaccine, BCG confers only partial protection against pulmonary disease, 
the most common and most transmissible form of the disease. Novel TB vaccines with better efficacy 
are urgently needed as part of the armoury of tools to eliminate TB by 2050. To properly design and 
implement these trials, several factors need to be borne in mind. These include, the most suited trial 
population, estimates of disease incidence, cohort retention and mortality. There are also diagnostic 
considerations, such as the utility of the chest radiograph and the possible role of the more prevalent 
non-tuberculous mycobacteria in confounding TB diagnosis. Finally, there are practical factors related 
to selection and development of research sites with the required trial infrastructure and expertise in 
high burden countries. This thesis explored the factors of design of new tuberculosis vaccine trials, 
diagnostic considerations and process of site development.
In chapter 1 the status of TB control and the need for new tools including a novel TB vaccine is 
examined. I explored the strengths and limitations of BCG vaccination, and reviewed the arguments 
around infant versus adult vaccination. In chapter 2, we found a high culture confirmed TB incidence 
among infants (0.2/100 pyo) in Western Kenya showing recent on-going transmission. Definite TB 
was associated with infant HIV infection, higher Keith Edward Scores. Modeling study data of inci-
dence and retention, we presented sample size estimates for future vaccine trials. In addition, cohort 
retention was positively associated with infant HIV infection and complete vaccination status at the 
four-month follow up visit. Thus, cohort characterization is useful in guiding future trial design and 
sample size estimates.
We examined post-neonatal mortality, its predictors, immediate and underlying causes of death in 
infants in chapter 3. Post-neonatal mortality was high in 2009 to 2011 (58/1000 pyo) but lower than 
preceding years. Infant HIV status and being born in a health facility were positive (HR 10.3; 95% 
CI: 6.40, 16.7) and negative predictors (Hazard Ratio (HR) 0.54; 95% CI: 0.34, 0.84) respectively, 
of mortality at 12 months. Mothers delivering in a health facility may have different health conscious-
ness, behaviour and access to health facilities that lead to longer term mortality benefits. Pneumonia 
and dehydration were the most frequently identified immediate causes of death. Since the study was 
conducted, pneumococcal and rotavirus vaccines were added to the national immunization schedule, 
therefore a decline in mortality is likely to be sustained. These gains are also positive for end-point 
detection in vaccine trials. In chapter 4 we examined the utility and inter-rater agreement of chest 
radiographs, a key diagnostic of composite TB endpoints in infant trials. Agreement on abnormalities 
consistent with TB was slight at best (k=0.14; (95%CI: 0.10 - 0.18) but was significantly better than 
agreement on any abnormality or normal radiographs. Hence the chest radiograph still has some 
utility as a diagnostic tool for vaccine trial endpoints despite its noted limitations. In chapter 5, 
the clinical relevance, incidence and types of Non-Tuberculous Mycobacteria were described. NTM 
incidence was 5.7/1,000 person-years; 95% CI (3.5, 8.7). We found no association between TST 
positivity and NTM isolation OR 1.15 (0.41, 3.25). Isolation in all cases represented colonisation and 
not disease, based on the American Thoracic Society Criteria. Infants diagnosed with TB were more 







confound TB diagnosis in future trials. In chapter 6 the process of TB vaccine trial site set-up from 
2007, infrastructure development and growth in expertise to conduct TB vaccine trials is described. 
Site development was gradual and incremental. Challenges encountered in each study were solved and 
turned into learning points, improving the implementation of future vaccine studies. Key lessons in 
site development include, the importance of conducting thorough epidemiological studies to provide 
context for clinical trials, including investigators in discussions of assays to be run on bio-banked 
samples. In context of the momentous breakthrough of an Ebola vaccine, I compare the TB vaccine 
development pipeline and suggest a shift to greater industry and government involvement, as well as 
greater global coordination of efforts by the WHO, will accelerate the development and approval of 
a novel TB vaccine. In chapter 7, I reviewed trial and post-trial considerations in selecting the most 
appropriate target population for future TB vaccine trials. Trial related factors included the incidence 
of disease and the impact on trial sample sizes, complexity of vaccine design for a particular high risk 
group. Post-trial factors included the availability of vaccination platforms, the quantity and speed of 
impact on the TB epidemic, among others. I also reviewed the TB vaccine candidates targeting infants 
in phase I and II trials.
cONclusIONs
The high incidence of TB among infants makes them a suitable trial population. On the other hand, 
they hardly transmit disease and therefore vaccinating them will have a much slower impact on the TB 
epidemic, adults could be a more urgent priority. Nevertheless, developing vaccination platforms to 
reach adults will be costly and logistically challenging.
The chest radiograph is still an important diagnostic tool in infant TB vaccine trials. NTMs among 
presumptive TB patients are either colonizing organisms or super-imposed on pulmonary TB. The de-
velopment of TB vaccine trial sites requires multi-national collaborations similar to what was observed 
during the Ebola outbreak of 2014-2016.
Recommendations
1. Selection of high risk populations will improve the speed and feasibility of TB vaccine trials. This 
may require inclusion of ignored sub-groups such as prisoners who suffer disproportionately high 
TB burden compared to the rest of the population.
2. Greater involvement of governments in both high and low burden countries will expedite the 
possibility of a new, more highly efficacious TB vaccine in our lifetimes.
3. Limited autopsies in infant trials may enhance our understanding of the disease process and 



















Tuberculose (TBC) is een groot probleem voor de volksgezondheid, waarbij de hoge morbiditeit en 
mortaliteit bij zuigelingen het probleem alleen maar groter maakt. Het enige erkende TBC-vaccin, 
BCG, biedt slechts gedeeltelijke bescherming tegen de pulmonale (long) vorm van de ziekte. Nieuwe 
TBC-vaccins met een betere werkzaamheid zijn dringend nodig als onderdeel van het arsenaal om 
TBC rond 2050 te kunnen elimineren. Om hier goed onderzoek naar te kunnen doen, is het essentieel 
om inzicht te hebben in de meest geschikte onderzoekspopulatie, schattingen van ziekte-incidentie, 
cohortretentie en mortaliteit van TBC in de te onderzoeken patiëntenpopulatie. Daarnaast zijn ook di-
agnostische overwegingen, zoals het nut van de thoraxfoto en de mogelijke rol van de niet-tuberculeuze 
mycobacteriën. Ten slotte zijn er praktische factoren in verband met de selectie en ontwikkeling van 
onderzoek sites met de vereiste studie-infrastructuur en expertise in landen waar TBC veel voorkomt. 
In dit proefschrift worden de ontwerp-factoren van nieuwe TBC-vaccintrials, diagnostische overwe-
gingen en het proces van ontwikkeling van de onderzoek locatie besproken.
In hoofdstuk 1 wordt de status van TBC-bestrijding beschreven en onderzochten we de sterke 
punten en beperkingen van BCG-vaccinatie. Daarbij brachten we ook de argumenten rond vaccinatie 
van zuigelingen versus volwassenen in kaart. In hoofdstuk 2 beschrijven we onze bevinding van de 
hoge TBC-incidentie bij zuigelingen in West-Kenia, wijzend op recente en doorgaande transmissie. 
Met het modelleren van onderzoeksgegevens over incidentie en retentie, geven we schattingen voor 
de omvang van steekproeven voor toekomstige vaccinonderzoek. Bovendien was cohortretentie 
positief geassocieerd met hiv-infectie bij kinderen en volledige vaccinatiestatus bij het follow-up 
bezoek van vier maanden. Daarom is cohort karakterisering nuttig bij het opstellen van toekomstig 
trial ontwerpen en het schatten van de omvang van steekproeven. Het onderzoek naar post-neonatale 
mortaliteit, de voorspellers ervan, directe en onderliggende doodsoorzaken bij zuigelingen staat be-
schreven in hoofdstuk 3. De post-neonatale mortaliteit was hoog in 2009 tot 2011 maar lager dan 
in voorgaande jaren. De hiv-status van baby’s en het geboren worden in een gezondheidsinstelling 
waren respectievelijk negatieve en positieve voorspellers van mortaliteit na 12 maanden. Moeders die 
in een gezondheidsinstelling bevielen, kunnen een ander gezondheidsbewustzijn, gedrag en toegang 
tot gezondheidsfaciliteiten hebben, die leiden tot voordelen op de langere termijn. Longontsteking 
en uitdroging waren de meest frequent geïdentificeerde directe doodsoorzaken bij de zuigelingen. 
Sinds het onderzoek werd uitgevoerd, werden pneumokokken- en rotavirusvaccins aan het nationale 
immunisatieschema toegevoegd, waardoor een daling van de mortaliteit waarschijnlijk zal aanhouden. 
In hoofdstuk 4 beschrijven we in welke mate er sprake is van verschil in beoordeling van thoraxfoto’s 
door verschillende artsen. De X-thorax is namelijk een belangrijk diagnostisch onderdeel van de 
samengestelde TBC-eindpunten in onderzoek van zuigelingen. Het bleek dat in de beoordeling van 
TBC-afwijkingen er een goede overeenstemming was tussen de verschillende beoordelaars, maar dat 
deze overeenstemming minder sterk was als het andere afwijkingen betrof. Toch kon gesteld worden 
dat dat de thoraxfoto nog steeds nut heeft als een diagnosticum bij Tbc-patiënten en dus in TBC 
(vaccinatie) studies, ondanks de geconstateerde beperkingen. In hoofdstuk 5 werden de klinische 
relevantie, incidentie en soorten van niet-tuberculeuze mycobacteriën (NTM) beschreven. We hebben 







van de American Thoracic Society, konden we bij geen van de patiënten waarbij een NTM-bacterie 
geïsoleerd werd, ziekte aantonen. Daarom is het onwaarschijnlijk dat NTM’s de diagnose van TBC in 
toekomstige studies zullen verstoren. In hoofdstuk 6 wordt het proces beschreven van het opzetten 
van een TBC-vaccintrial locatie, de ontwikkeling van infrastructuur en de groei van expertise voor het 
uitvoeren van trials met TBC-vaccinatie. De ontwikkeling van de site verliep geleidelijk en stapsgewijs. 
Uitdagingen in elk onderzoek werden opgelost en omgezet in leerpunten, waardoor de uitvoering 
van toekomstige vaccintrials mogelijk kan worden verbeterd. In de context van de gedenkwaardige 
doorbraak van een ebolavaccin staat in hoofdstuk 6 ook de vergelijking van de ontwikkelingspijplijn 
voor TBC-vaccins. Daarbij valt op dat er een mogelijk meerwaarde is als er een grotere betrokkenheid 
van de industrie en de overheid zou zijn in de TBC-vaccinatiestudies, evenals een grotere wereldwijde 
coördinatie van inspanningen door de WHO.
cONclusIes
De (triest) hoge incidentie van TBC bij zuigelingen maakt hen tot een geschikte populatie om TBC-
vaccinonderzoek in te doen. Aan de andere kant is de transmissie van TBC vanuit zuigelingen zeer 
beperkt, waardoor ook een goed vaccin slechts heel langzaam impact zal hebben op de TBC-epidemie. 
De röntgenfoto van de longen is nog steeds een belangrijk diagnosticum en bruikbaar als uitkomst 
parameter in het onderzoek naar de effectiviteit van TBC-vaccins in zuigelingen. NTM-infecties bij 
patiënten die verdacht worden van TBC zijn ofwel slechts koloniserende organismen of zijn additioneel 
aan de een M. tuberculosis infectie. De ontwikkeling van nieuwe triallocaties voor TBC-vaccinstudies 
vereist multinationale samenwerkingsverbanden.
aanbevelingen
1. Selectie van patiënten-populaties met een hoge kans op TBC zal de snelheid en haalbaarheid van 
vaccintrials verbeteren. Hierbij kan gedacht worden aan het opnemen van bijvoorbeeld gevange-
nen (bekend vanwege een hoge TBC-incidentie) in toekomstige studies.
2. Een grotere betrokkenheid van overheden in zowel landen met een hoge als met een lage TBC-
belasting zal de mogelijkheid van een nieuw, zeer doeltreffend TBC-vaccin binnen onze generatie 
versnellen.
3. Beperkte autopsies in kindertrials kunnen ons begrip van het ziekteproces verbeteren en de eind-
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